<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Multiple myeloma - Wikipedia, the free encyclopedia</title>
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />
<meta name="generator" content="MediaWiki 1.23wmf19" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Multiple_myeloma" />
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Multiple_myeloma&amp;action=edit" />
<link rel="edit" title="Edit this page" href="/w/index.php?title=Multiple_myeloma&amp;action=edit" />
<link rel="apple-touch-icon" href="//bits.wikimedia.org/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="//bits.wikimedia.org/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="http://en.wikipedia.org/wiki/Multiple_myeloma" />
<link rel="stylesheet" href="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.rtlcite%2Cwikihiero%7Cext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.ui.button%7Cskins.common.interface%7Cskins.vector.styles&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: enwiki:resourceloader:filter:minify-css:7:3904d24a08aa08f6a68dc338f9be277e */</style>

<script src="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Multiple_myeloma","wgTitle":"Multiple myeloma","wgCurRevisionId":599977452,"wgRevisionId":599977452,"wgArticleId":292137,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles with inconsistent citation formats","Wikipedia articles needing clarification from December 2013","All articles with unsourced statements","Articles with unsourced statements from March 2012","Articles with unsourced statements from February 2007","Articles with unsourced statements from July 2010","Articles using fixed number of columns in reflist","Articles with Open Directory Project links","Hematologic malignant neoplasms"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Multiple_myeloma","wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"templateEditor":false,"templates":false,"preview":false,"previewDialog":false,"publish":false,"toc":false},"wgBetaFeaturesFeatures":[],"wgVisualEditor":{"isPageWatched":false,"magnifyClipIconURL":"//bits.wikimedia.org/static-1.23wmf19/skins/common/images/magnify-clip.png","pageLanguageCode":"en","pageLanguageDir":"ltr","svgMaxSize":2048},"wikilove-recipient":"","wikilove-anon":0,"wgGuidedTourHelpGuiderUrl":"Help:Guided tours/guider","wgFlowTermsOfUseEdit":"By saving changes, you agree to our \u003Ca class=\"external text\" href=\"//wikimediafoundation.org/wiki/Terms_of_use\"\u003ETerms of Use\u003C/a\u003E and agree to irrevocably release your text under the \u003Ca rel=\"nofollow\" class=\"external text\" href=\"//creativecommons.org/licenses/by-sa/3.0\"\u003ECC BY-SA 3.0 License\u003C/a\u003E and \u003Ca class=\"external text\" href=\"//en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License\"\u003EGFDL\u003C/a\u003E","wgULSAcceptLanguageList":["nb-no","nb","no","nn","en-us","en","da"],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgWikibaseItemId":"Q467635"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function(){mw.user.options.set({"ccmeonemails":0,"cols":80,"date":"default","diffonly":0,"disablemail":0,"editfont":"default","editondblclick":0,"editsectiononrightclick":0,"enotifminoredits":0,"enotifrevealaddr":0,"enotifusertalkpages":1,"enotifwatchlistpages":0,"extendwatchlist":0,"fancysig":0,"forceeditsummary":0,"gender":"unknown","hideminor":0,"hidepatrolled":0,"imagesize":2,"math":0,"minordefault":0,"newpageshidepatrolled":0,"nickname":"","norollbackdiff":0,"numberheadings":0,"previewonfirst":0,"previewontop":1,"rcdays":7,"rclimit":50,"rememberpassword":0,"rows":25,"showhiddencats":false,"shownumberswatching":1,"showtoolbar":1,"skin":"vector","stubthreshold":0,"thumbsize":4,"underline":2,"uselivepreview":0,"usenewrc":0,"watchcreations":1,"watchdefault":0,"watchdeletion":0,"watchlistdays":3,"watchlisthideanons":0,"watchlisthidebots":0,"watchlisthideliu":0,"watchlisthideminor":0,"watchlisthideown":0,"watchlisthidepatrolled":0,"watchmoves":0,
"wllimit":250,"useeditwarning":1,"prefershttps":1,"flaggedrevssimpleui":1,"flaggedrevsstable":0,"flaggedrevseditdiffs":true,"flaggedrevsviewdiffs":false,"usebetatoolbar":1,"usebetatoolbar-cgd":1,"visualeditor-enable":0,"visualeditor-enable-experimental":0,"visualeditor-betatempdisable":0,"wikilove-enabled":1,"echo-subscriptions-web-page-review":true,"echo-subscriptions-email-page-review":false,"ep_showtoplink":false,"ep_bulkdelorgs":false,"ep_bulkdelcourses":true,"ep_showdyk":true,"echo-subscriptions-web-education-program":true,"echo-subscriptions-email-education-program":false,"echo-notify-show-link":true,"echo-show-alert":true,"echo-email-frequency":0,"echo-email-format":"html","echo-subscriptions-email-system":true,"echo-subscriptions-web-system":true,"echo-subscriptions-email-other":false,"echo-subscriptions-web-other":true,"echo-subscriptions-email-edit-user-talk":false,"echo-subscriptions-web-edit-user-talk":true,"echo-subscriptions-email-reverted":false,
"echo-subscriptions-web-reverted":true,"echo-subscriptions-email-article-linked":false,"echo-subscriptions-web-article-linked":false,"echo-subscriptions-email-mention":false,"echo-subscriptions-web-mention":true,"echo-subscriptions-web-edit-thank":true,"echo-subscriptions-email-edit-thank":false,"echo-subscriptions-web-flow-discussion":true,"echo-subscriptions-email-flow-discussion":false,"gettingstarted-task-toolbar-show-intro":true,"uls-preferences":"","language":"en","variant-gan":"gan","variant-iu":"iu","variant-kk":"kk","variant-ku":"ku","variant-shi":"shi","variant-sr":"sr","variant-tg":"tg","variant-uz":"uz","variant-zh":"zh","searchNs0":true,"searchNs1":false,"searchNs2":false,"searchNs3":false,"searchNs4":false,"searchNs5":false,"searchNs6":false,"searchNs7":false,"searchNs8":false,"searchNs9":false,"searchNs10":false,"searchNs11":false,"searchNs12":false,"searchNs13":false,"searchNs14":false,"searchNs15":false,"searchNs100":false,"searchNs101":false,"searchNs108":false,
"searchNs109":false,"searchNs118":false,"searchNs119":false,"searchNs446":false,"searchNs447":false,"searchNs710":false,"searchNs711":false,"searchNs828":false,"searchNs829":false,"gadget-teahouse":1,"gadget-ReferenceTooltips":1,"gadget-DRN-wizard":1,"gadget-charinsert":1,"gadget-mySandbox":1,"variant":"en"});},{},{});mw.loader.implement("user.tokens",function(){mw.user.tokens.set({"editToken":"+\\","patrolToken":false,"watchToken":false});},{},{});
/* cache key: enwiki:resourceloader:filter:minify-js:7:868e43d07ede2616d2d1dc3507cd8145 */
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","skins.vector.compactPersonalBar.defaultTracking","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","wikibase.client.init","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" /><!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static-1.23wmf19/skins/vector/csshover.min.htc")}</style><![endif]--></head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Multiple_myeloma skin-vector action-view vector-animateLayout">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>
			<div id="mw-js-message" style="display:none;"></div>
						<div id="siteNotice"><!-- CentralNotice --></div>
						<h1 id="firstHeading" class="firstHeading" lang="en"><span dir="auto">Multiple myeloma</span></h1>
						<div id="bodyContent">
								<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-navigation">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><table class="infobox" cellspacing="3" style="border-spacing:3px;width:22em;">
<tr>
<th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background-color: lightgrey;">Multiple myeloma</th>
</tr>
<tr>
<td colspan="2" style="text-align:center;"><i>Classification and external resources</i></td>
</tr>
<tr>
<td colspan="2" style="text-align:center;"><a href="/wiki/File:Plasmacytoma_ultramini1.jpg" class="image"><img alt="Plasmacytoma ultramini1.jpg" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/10/Plasmacytoma_ultramini1.jpg/230px-Plasmacytoma_ultramini1.jpg" width="230" height="169" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/10/Plasmacytoma_ultramini1.jpg/345px-Plasmacytoma_ultramini1.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/10/Plasmacytoma_ultramini1.jpg/460px-Plasmacytoma_ultramini1.jpg 2x" /></a><br />
<div><a href="/wiki/Micrograph" title="Micrograph">Micrograph</a> of a <a href="/wiki/Plasmacytoma" title="Plasmacytoma">plasmacytoma</a>, the <a href="/wiki/Histology" title="Histology">histologic</a> correlate of multiple myeloma. <a href="/wiki/H%26E_stain" title="H&amp;E stain">H&amp;E stain</a></div>
</td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/ICD-10" title="ICD-10">10</a></th>
<td><a href="/wiki/ICD-10_Chapter_C" title="ICD-10 Chapter C" class="mw-redirect">C</a><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2010/en#/C90.0">90.0</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9</a></th>
<td><a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=203.0">203.0</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/International_Classification_of_Diseases_for_Oncology" title="International Classification of Diseases for Oncology">ICD-O:</a></th>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I97323/">9732/3</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/OMIM" title="OMIM" class="mw-redirect">OMIM</a></th>
<td><a rel="nofollow" class="external text" href="http://omim.org/entry/254500">254500</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb8628.htm">8628</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/ency/article/000583.htm">000583</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a rel="nofollow" class="external text" href="http://www.emedicine.com/med/topic1521.htm">med/1521</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></th>
<td><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&amp;term=D009101">D009101</a></td>
</tr>
</table>
<p><b>Multiple myeloma</b> (from Greek <i>myelo-</i>, marrow), also known as <b>plasma cell myeloma</b> or <b>Kahler's disease</b> (after <a href="/wiki/Otto_Kahler" title="Otto Kahler">Otto Kahler</a>), is a <a href="/wiki/Cancer" title="Cancer">cancer</a> of <a href="/wiki/Plasma_cell" title="Plasma cell">plasma cells</a>, a type of <a href="/wiki/White_blood_cell" title="White blood cell">white blood cell</a> normally responsible for producing <a href="/wiki/Antibody" title="Antibody">antibodies</a>.<sup id="cite_ref-Raab_1-0" class="reference"><a href="#cite_note-Raab-1"><span>[</span>1<span>]</span></a></sup> In multiple myeloma, collections of abnormal plasma cells accumulate in the <a href="/wiki/Bone_marrow" title="Bone marrow">bone marrow</a>, where they interfere with the production of normal blood cells. Most cases of myeloma also feature the production of a <a href="/wiki/Paraprotein" title="Paraprotein">paraprotein</a>—an abnormal antibody which can cause <a href="/wiki/Kidney" title="Kidney">kidney</a> problems. Bone lesions and <a href="/wiki/Hypercalcemia" title="Hypercalcemia" class="mw-redirect">hypercalcemia</a> (high blood calcium levels) are also often encountered.<sup id="cite_ref-Raab_1-1" class="reference"><a href="#cite_note-Raab-1"><span>[</span>1<span>]</span></a></sup></p>
<p>Myeloma is diagnosed with <a href="/wiki/Blood_test" title="Blood test">blood tests</a> (serum <a href="/wiki/Protein_electrophoresis" title="Protein electrophoresis" class="mw-redirect">protein electrophoresis</a>, serum free kappa/lambda light chain assay), <a href="/wiki/Bone_marrow_examination" title="Bone marrow examination">bone marrow examination</a>, urine protein electrophoresis, and X-rays of commonly involved bones. Myeloma is generally thought to be incurable but highly treatable. Remissions may be induced with <a href="/wiki/Glucocorticoid" title="Glucocorticoid">steroids</a>, <a href="/wiki/Chemotherapy" title="Chemotherapy">chemotherapy</a>, <a href="/wiki/Proteasome_inhibitor" title="Proteasome inhibitor">proteasome inhibitors</a>, immunomodulatory drugs (IMiDs) such as <a href="/wiki/Thalidomide" title="Thalidomide">thalidomide</a> or <a href="/wiki/Lenalidomide" title="Lenalidomide">lenalidomide</a>, and <a href="/wiki/Stem_cell_transplant" title="Stem cell transplant" class="mw-redirect">stem cell transplants</a>. <a href="/wiki/Radiation_therapy" title="Radiation therapy">Radiation therapy</a> is sometimes used to reduce pain from bone lesions.<sup id="cite_ref-Raab_1-2" class="reference"><a href="#cite_note-Raab-1"><span>[</span>1<span>]</span></a></sup></p>
<p>Myeloma develops in 1–4 per 100,000 people per year. It is more common in men and, for unknown reasons, is twice as common in <a href="/wiki/African-American" title="African-American" class="mw-redirect">African-Americans</a> as it is in <a href="/wiki/White_American" title="White American">European-Americans</a>. With conventional treatment, median survival is 3–4 years, which may be extended to 5–7 years or longer with advanced treatments. Multiple myeloma is the second most common <a href="/wiki/Hematological_malignancy" title="Hematological malignancy">hematological malignancy</a> in the U.S. (after <a href="/wiki/Non-Hodgkin_lymphoma" title="Non-Hodgkin lymphoma">non-Hodgkin lymphoma</a>), and constitutes 1% of all cancers.<sup id="cite_ref-Raab_1-3" class="reference"><a href="#cite_note-Raab-1"><span>[</span>1<span>]</span></a></sup></p>
<p></p>
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Signs_and_symptoms"><span class="tocnumber">1</span> <span class="toctext">Signs and symptoms</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Bone_pain"><span class="tocnumber">1.1</span> <span class="toctext">Bone pain</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Anemia"><span class="tocnumber">1.2</span> <span class="toctext">Anemia</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Renal_failure"><span class="tocnumber">1.3</span> <span class="toctext">Renal failure</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Infection"><span class="tocnumber">1.4</span> <span class="toctext">Infection</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Neurological_symptoms"><span class="tocnumber">1.5</span> <span class="toctext">Neurological symptoms</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-7"><a href="#Diagnosis"><span class="tocnumber">2</span> <span class="toctext">Diagnosis</span></a>
<ul>
<li class="toclevel-2 tocsection-8"><a href="#Investigations"><span class="tocnumber">2.1</span> <span class="toctext">Investigations</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Workup"><span class="tocnumber">2.2</span> <span class="toctext">Workup</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Diagnostic_criteria"><span class="tocnumber">2.3</span> <span class="toctext">Diagnostic criteria</span></a></li>
<li class="toclevel-2 tocsection-11"><a href="#Staging"><span class="tocnumber">2.4</span> <span class="toctext">Staging</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-12"><a href="#Pathophysiology"><span class="tocnumber">3</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-1 tocsection-13"><a href="#Treatment"><span class="tocnumber">4</span> <span class="toctext">Treatment</span></a>
<ul>
<li class="toclevel-2 tocsection-14"><a href="#Initial_therapy"><span class="tocnumber">4.1</span> <span class="toctext">Initial therapy</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Maintenance_therapy"><span class="tocnumber">4.2</span> <span class="toctext">Maintenance therapy</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Relapse"><span class="tocnumber">4.3</span> <span class="toctext">Relapse</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-17"><a href="#Prognosis"><span class="tocnumber">5</span> <span class="toctext">Prognosis</span></a>
<ul>
<li class="toclevel-2 tocsection-18"><a href="#Genetic_testing"><span class="tocnumber">5.1</span> <span class="toctext">Genetic testing</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-19"><a href="#Epidemiology"><span class="tocnumber">6</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1 tocsection-20"><a href="#Other_animals"><span class="tocnumber">7</span> <span class="toctext">Other animals</span></a></li>
<li class="toclevel-1 tocsection-21"><a href="#See_also"><span class="tocnumber">8</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-22"><a href="#References"><span class="tocnumber">9</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-23"><a href="#External_links"><span class="tocnumber">10</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
<p></p>
<h2><span class="mw-headline" id="Signs_and_symptoms">Signs and symptoms</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=1" title="Edit section: Signs and symptoms">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Because many organs can be affected by myeloma, the symptoms and signs vary greatly. A <a href="/wiki/Mnemonic" title="Mnemonic">mnemonic</a> sometimes used to remember the common symptoms of multiple myeloma is <i>CRAB</i>: C = Calcium (elevated), R = Renal failure, A = Anemia, B = Bone lesions.<sup id="cite_ref-IMWG_2-0" class="reference"><a href="#cite_note-IMWG-2"><span>[</span>2<span>]</span></a></sup> Myeloma has many other possible symptoms, including opportunistic infections (e.g., pneumonia.) CRAB symptoms and proliferation of monoclonal plasma cells in the bone marrow are part of the diagnostic criteria of multiple myeloma.</p>
<h3><span class="mw-headline" id="Bone_pain">Bone pain</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=2" title="Edit section: Bone pain">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Blausen_0656_MultipleMyeloma.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ef/Blausen_0656_MultipleMyeloma.png/220px-Blausen_0656_MultipleMyeloma.png" width="220" height="293" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ef/Blausen_0656_MultipleMyeloma.png/330px-Blausen_0656_MultipleMyeloma.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ef/Blausen_0656_MultipleMyeloma.png/440px-Blausen_0656_MultipleMyeloma.png 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Blausen_0656_MultipleMyeloma.png" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf19/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Illustration showing the most common site of bone lesions in vertebrae</div>
</div>
</div>
<p>Bone pain affects almost 70% of patients and is the most common symptom.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3"><span>[</span>3<span>]</span></a></sup> Myeloma bone pain usually involves the spine and ribs, and worsens with activity. Persistent localized pain may indicate a pathological <a href="/wiki/Bone_fracture" title="Bone fracture">bone fracture</a>. Involvement of the vertebrae may lead to <a href="/wiki/Spinal_cord_compression" title="Spinal cord compression">spinal cord compression</a>. Myeloma bone disease is due to the overexpression of Receptor Activator for Nuclear Factor κ B Ligand (<a href="/wiki/RANKL" title="RANKL">RANKL</a>) by bone marrow stroma. RANKL activates <a href="/wiki/Osteoclast" title="Osteoclast">osteoclasts</a>, which resorb bone. The resultant bone lesions are lytic (cause breakdown) in nature and are best seen in plain radiographs, which may show "punched-out" resorptive lesions (including the "pepper pot" appearance of the <a href="/wiki/Skull" title="Skull">skull</a> on radiography). The breakdown of bone also leads to release of <a href="/wiki/Calcium" title="Calcium">calcium</a> into the blood, leading to <a href="/wiki/Hypercalcemia" title="Hypercalcemia" class="mw-redirect">hypercalcemia</a> and its associated symptoms.</p>
<h3><span class="mw-headline" id="Anemia">Anemia</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=3" title="Edit section: Anemia">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The <a href="/wiki/Anemia" title="Anemia">anemia</a> found in myeloma is usually <a href="/wiki/Normocytic" title="Normocytic" class="mw-redirect">normocytic</a> and <a href="/wiki/Normochromic" title="Normochromic" class="mw-redirect">normochromic</a>. It results from the replacement of normal bone marrow by infiltrating tumor cells and inhibition of normal red blood cell production (<a href="/wiki/Hematopoiesis" title="Hematopoiesis" class="mw-redirect">hematopoiesis</a>) by <a href="/wiki/Cytokines" title="Cytokines" class="mw-redirect">cytokines</a>.</p>
<h3><span class="mw-headline" id="Renal_failure">Renal failure</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=4" title="Edit section: Renal failure">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Renal_failure" title="Renal failure">Renal failure</a> may develop both <a href="/wiki/Acute_renal_failure" title="Acute renal failure" class="mw-redirect">acutely</a> and <a href="/wiki/Chronic_renal_failure" title="Chronic renal failure" class="mw-redirect">chronically</a>.</p>
<p>The most common cause of renal failure in multiple myeloma is due to proteins secreted by the malignant cells. Myeloma cells produce monoclonal proteins of varying types, most commonly immunoglobulins (antibodies) and free light chains, resulting in abnormally high levels of these proteins in the blood. Depending on the size of these proteins, they may be excreted through the kidneys. Kidneys can be damaged by the tubulopathic effects of proteins or light chains.<sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Please_clarify" title="Wikipedia:Please clarify"><span title="The text near this tag may need clarification or removal of jargon. (December 2013)">clarification needed</span></a></i>]</sup> Increased bone resorption leads to hypercalcemia and causes nephrocalcinosis thereby contributing to the renal failure. <a href="/wiki/Amyloidosis" title="Amyloidosis">Amyloidosis</a> is a distant third in the causation. Patients with Amyloidosis have high levels of <a href="/wiki/Amyloid_protein" title="Amyloid protein" class="mw-redirect">Amyloid</a> protein that can be excreted through the kidneys and cause damage to the kidneys and other organs.</p>
<p>Light chains produce myriad effects which can manifest as the <a href="/wiki/Fanconi_syndrome" title="Fanconi syndrome">Fanconi syndrome</a> (type II <a href="/wiki/Renal_tubular_acidosis" title="Renal tubular acidosis">renal tubular acidosis</a>).</p>
<p>Other causes include <a href="/wiki/Hyperuricemia" title="Hyperuricemia">hyperuricemia</a>, recurrent infections (<a href="/wiki/Pyelonephritis" title="Pyelonephritis">pyelonephritis</a>), and local infiltration of <a href="/wiki/Tumor" title="Tumor" class="mw-redirect">tumor</a> cells.</p>
<h3><span class="mw-headline" id="Infection">Infection</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=5" title="Edit section: Infection">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The most common infections are <a href="/wiki/Pneumonia" title="Pneumonia">pneumonias</a> and <a href="/wiki/Pyelonephritis" title="Pyelonephritis">pyelonephritis</a>. Common pneumonia <a href="/wiki/Pathogen" title="Pathogen">pathogens</a> include <i><a href="/wiki/Streptococcus_pneumoniae" title="Streptococcus pneumoniae">S. pneumoniae</a></i>, <i><a href="/wiki/Staphylococcus_aureus" title="Staphylococcus aureus">S. aureus</a></i>, and <i><a href="/wiki/Klebsiella_pneumoniae" title="Klebsiella pneumoniae">K. pneumoniae</a></i>, while common pathogens causing <a href="/wiki/Pyelonephritis" title="Pyelonephritis">pyelonephritis</a> include <i><a href="/wiki/Escherichia_coli" title="Escherichia coli">E. coli</a></i> and other <a href="/wiki/Gram-negative" title="Gram-negative" class="mw-redirect">gram-negative</a> organisms. The greatest risk period for the occurrence of infection is in the initial few months after the start of chemotherapy.<sup id="cite_ref-pmid8033429_4-0" class="reference"><a href="#cite_note-pmid8033429-4"><span>[</span>4<span>]</span></a></sup> The increased risk of infection is due to immune deficiency. Although the total <a href="/wiki/Immunoglobulin" title="Immunoglobulin" class="mw-redirect">immunoglobulin</a> level is typically elevated in multiple myeloma, the majority of the antibodies are ineffective monoclonal antibodies from the clonal plasma cell. A selected group of patients with documented <a href="/wiki/Hypogammaglobulinemia" title="Hypogammaglobulinemia">hypogammaglobulinemia</a> may benefit from replacement <a href="/wiki/Immunoglobulin" title="Immunoglobulin" class="mw-redirect">immunoglobulin</a> therapy to reduce the risk of infection.<sup id="cite_ref-pmid7730490_5-0" class="reference"><a href="#cite_note-pmid7730490-5"><span>[</span>5<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Neurological_symptoms">Neurological symptoms</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=6" title="Edit section: Neurological symptoms">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Common problems are <a href="/wiki/Weakness" title="Weakness">weakness</a>, <a href="/wiki/Confusion" title="Confusion" class="mw-redirect">confusion</a> and <a href="/wiki/Fatigue_(medical)" title="Fatigue (medical)">fatigue</a> due to <a href="/wiki/Hypercalcemia" title="Hypercalcemia" class="mw-redirect">hypercalcemia</a>. <a href="/wiki/Headache" title="Headache">Headache</a>, visual changes and <a href="/wiki/Retinopathy" title="Retinopathy">retinopathy</a> may be the result of <a href="/wiki/Hyperviscosity" title="Hyperviscosity" class="mw-redirect">hyperviscosity</a> of the blood depending on the properties of the <a href="/wiki/Paraprotein" title="Paraprotein">paraprotein</a>. Finally, there may be <a href="/wiki/Radicular_pain" title="Radicular pain">radicular pain</a>, loss of <a href="/wiki/Bowel" title="Bowel" class="mw-redirect">bowel</a> or bladder control (due to involvement of <a href="/wiki/Spinal_cord" title="Spinal cord">spinal cord</a> leading to <a href="/wiki/Spinal_cord_compression" title="Spinal cord compression">cord compression</a>) or <a href="/wiki/Carpal_tunnel_syndrome" title="Carpal tunnel syndrome">carpal tunnel syndrome</a> and other <a href="/wiki/Neuropathies" title="Neuropathies" class="mw-redirect">neuropathies</a> (due to infiltration of <a href="/wiki/Peripheral_nerves" title="Peripheral nerves" class="mw-redirect">peripheral nerves</a> by <a href="/wiki/Amyloid" title="Amyloid">amyloid</a>). It may give rise to <a href="/wiki/Paraplegia" title="Paraplegia">paraplegia</a> in late presenting cases.</p>
<p>When the disease is well-controlled, there are often neurological symptoms resulting from current treatments, many of which can cause peripheral neuropathy, manifesting itself as numbness or pain in the hands, feet, and lower legs. There can also be bowel issues caused by neurotoxic treatment regimens.</p>
<h2><span class="mw-headline" id="Diagnosis">Diagnosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=7" title="Edit section: Diagnosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Investigations">Investigations</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=8" title="Edit section: Investigations">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Monoclonal_gammopathy_Multiple_Myeloma.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Monoclonal_gammopathy_Multiple_Myeloma.png/220px-Monoclonal_gammopathy_Multiple_Myeloma.png" width="220" height="89" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Monoclonal_gammopathy_Multiple_Myeloma.png/330px-Monoclonal_gammopathy_Multiple_Myeloma.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Monoclonal_gammopathy_Multiple_Myeloma.png/440px-Monoclonal_gammopathy_Multiple_Myeloma.png 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Monoclonal_gammopathy_Multiple_Myeloma.png" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf19/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Serum <a href="/wiki/Protein_electrophoresis" title="Protein electrophoresis" class="mw-redirect">protein electrophoresis</a> showing a paraprotein (peak in the gamma zone) in a patient with multiple myeloma.</div>
</div>
</div>
<p>The presence of unexplained <a href="/wiki/Anemia" title="Anemia">anemia</a>, <a href="/wiki/Kidney" title="Kidney">kidney</a> dysfunction, a high <a href="/wiki/Erythrocyte_sedimentation_rate" title="Erythrocyte sedimentation rate">erythrocyte sedimentation rate</a> (ESR), lytic bone lesions, elevated <a href="/wiki/Beta-2_microglobulin" title="Beta-2 microglobulin">beta-2 microglobulin</a>, and/or a high serum <a href="/wiki/Protein" title="Protein">protein</a> (especially raised globulins or <a href="/wiki/Immunoglobulin" title="Immunoglobulin" class="mw-redirect">immunoglobulin</a>) may prompt further testing. The globulin level may be normal in established disease. A doctor will request <a href="/wiki/Protein_electrophoresis" title="Protein electrophoresis" class="mw-redirect">protein electrophoresis</a> of the blood and urine, which might show the presence of a <a href="/wiki/Paraprotein" title="Paraprotein">paraprotein</a> (monoclonal protein, or M protein) band, with or without reduction of the other (normal) immunoglobulins (known as immune paresis). One type of paraprotein is the <a href="/wiki/Bence_Jones_protein" title="Bence Jones protein">Bence Jones protein</a> which is a urinary paraprotein composed of free light chains (see below). Quantitative measurements of the paraprotein are necessary to establish a diagnosis and to monitor the disease. The paraprotein is an abnormal <a href="/wiki/Immunoglobulin" title="Immunoglobulin" class="mw-redirect">immunoglobulin</a> produced by the tumor clone. Very rarely, the myeloma is <i>nonsecretory</i> (not producing immunoglobulins).</p>
<p>In theory, multiple myeloma can produce all classes of immunoglobulin, but <a href="/wiki/IgG" title="IgG" class="mw-redirect">IgG</a> paraproteins are most common, followed by <a href="/wiki/IgA" title="IgA" class="mw-redirect">IgA</a> and <a href="/wiki/IgM" title="IgM" class="mw-redirect">IgM</a>. <a href="/wiki/IgD" title="IgD" class="mw-redirect">IgD</a> and <a href="/wiki/IgE" title="IgE" class="mw-redirect">IgE</a> myeloma are very rare. In addition, <a href="/wiki/Immunoglobulin_light_chain" title="Immunoglobulin light chain">light</a> and or <a href="/wiki/Immunoglobulin_heavy_chain" title="Immunoglobulin heavy chain">heavy chains</a> (the building blocks of <a href="/wiki/Antibodies" title="Antibodies" class="mw-redirect">antibodies</a>) may be secreted in isolation: κ- or λ-light chains or any of the five types of heavy chains (α-, γ-, δ-, ε- or μ-heavy chains).</p>
<p>Additional findings may include: a raised <a href="/wiki/Calcium" title="Calcium">calcium</a> (when <a href="/wiki/Osteoclasts" title="Osteoclasts" class="mw-redirect">osteoclasts</a> are breaking down bone, releasing <a href="/wiki/Calcium" title="Calcium">calcium</a> into the bloodstream), raised serum <a href="/wiki/Creatinine" title="Creatinine">creatinine</a> due to reduced <a href="/wiki/Renal_function" title="Renal function">renal function</a>, which is mainly due to casts of paraprotein deposition in the <a href="/wiki/Kidney" title="Kidney">kidney</a>, although the cast may also contain complete immunoglobulins, <a href="/wiki/Tamm-Horsfall_protein" title="Tamm-Horsfall protein" class="mw-redirect">Tamm-Horsfall protein</a> and <a href="/wiki/Albumin" title="Albumin">albumin</a>.<sup id="cite_ref-Robbins_6-0" class="reference"><a href="#cite_note-Robbins-6"><span>[</span>6<span>]</span></a></sup></p>
<ul class="gallery mw-gallery-traditional">
<li class="gallerybox" style="width: 155px">
<div style="width: 155px">
<div class="thumb" style="width: 150px;">
<div style="margin:30px auto;"><a href="/wiki/File:Multiple_myeloma_(2)_HE_stain.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/2/21/Multiple_myeloma_%282%29_HE_stain.jpg/120px-Multiple_myeloma_%282%29_HE_stain.jpg" width="120" height="90" /></a></div>
</div>
<div class="gallerytext">
<p><a href="/wiki/Bone_marrow" title="Bone marrow">Bone marrow</a> aspirate showing the histologic correlate of multiple myeloma under the microscope. <a href="/wiki/H%26E_stain" title="H&amp;E stain">H&amp;E stain</a>.</p>
</div>
</div>
</li>
<li class="gallerybox" style="width: 155px">
<div style="width: 155px">
<div class="thumb" style="width: 150px;">
<div style="margin:24px auto;"><a href="/wiki/File:Plasmacytoma1.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4e/Plasmacytoma1.jpg/120px-Plasmacytoma1.jpg" width="120" height="102" /></a></div>
</div>
<div class="gallerytext">
<p>Plasmacytoma. H&amp;E stain.</p>
</div>
</div>
</li>
<li class="gallerybox" style="width: 155px">
<div style="width: 155px">
<div class="thumb" style="width: 150px;">
<div style="margin:30px auto;"><a href="/wiki/File:Cast_nephropathy_-_2_cropped_-_very_high_mag.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/fc/Cast_nephropathy_-_2_cropped_-_very_high_mag.jpg/120px-Cast_nephropathy_-_2_cropped_-_very_high_mag.jpg" width="120" height="90" /></a></div>
</div>
<div class="gallerytext">
<p><a href="/wiki/Micrograph" title="Micrograph">Micrograph</a> showing myeloma <a href="/wiki/Cast_nephropathy" title="Cast nephropathy" class="mw-redirect">cast nephropathy</a> in a<a href="/wiki/Kidney_biopsy" title="Kidney biopsy" class="mw-redirect">kidney biopsy</a>. Hyaline casts are PAS positive (dark pink/red - right of image). Myelomatous casts are PAS negative (pale pink - left of image). <a href="/wiki/PAS_stain" title="PAS stain" class="mw-redirect">PAS stain</a>.</p>
</div>
</div>
</li>
<li class="gallerybox" style="width: 155px">
<div style="width: 155px">
<div class="thumb" style="width: 150px;">
<div style="margin:30px auto;"><a href="/wiki/File:Russell_and_Dutcher_bodies.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/9/9e/Russell_and_Dutcher_bodies.jpg/120px-Russell_and_Dutcher_bodies.jpg" width="120" height="90" /></a></div>
</div>
<div class="gallerytext">
<p>Atypical plasma cell infiltrate with both Russell (cytoplasmic) and Dutcher (nuclear) bodies (H&amp;E, 50x).</p>
</div>
</div>
</li>
</ul>
<h3><span class="mw-headline" id="Workup">Workup</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=9" title="Edit section: Workup">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Multiple_myeloma_skull_CT_arrows.PNG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/6c/Multiple_myeloma_skull_CT_arrows.PNG/220px-Multiple_myeloma_skull_CT_arrows.PNG" width="220" height="99" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/6c/Multiple_myeloma_skull_CT_arrows.PNG/330px-Multiple_myeloma_skull_CT_arrows.PNG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/6c/Multiple_myeloma_skull_CT_arrows.PNG/440px-Multiple_myeloma_skull_CT_arrows.PNG 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Multiple_myeloma_skull_CT_arrows.PNG" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf19/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
A 59 year-old patient presented with a left facial droop and a known history of multiple myeloma. A <a href="/wiki/Computed_tomography" title="Computed tomography" class="mw-redirect">CT</a> of the <a href="/wiki/Brain" title="Brain">brain</a> was performed looking for a <a href="/wiki/Cerebrum" title="Cerebrum">cerebral</a> cause. The brain appeared normal. Close inspection revealed a lytic lesion in the left <a href="/wiki/Temporal_bone" title="Temporal bone">temporal bone</a> (right side of image), and focused reconstructions of the <a href="/wiki/Petrous_portion_of_the_temporal_bone" title="Petrous portion of the temporal bone" class="mw-redirect">petrous</a> temporal bones confirmed a lytic lesion involving the mastoid segment of the <a href="/wiki/Facial_nerve" title="Facial nerve">facial nerve</a> canal. Red arrows: lesion; green arrow: normal contralateral facial nerve canal. The lytic lesion was one of many in the skull and is consistent with a myeloma deposit.</div>
</div>
</div>
<p>The workup of suspected multiple myeloma includes a <a href="/wiki/Skeletal_survey" title="Skeletal survey">skeletal survey</a>. This is a series of <a href="/wiki/X-ray" title="X-ray">X-rays</a> of the skull, <a href="/wiki/Axial_skeleton" title="Axial skeleton">axial skeleton</a> and proximal long bones. Myeloma activity sometimes appear as "lytic lesions" (with local disappearance of normal bone due to resorption), and on the skull <a href="/wiki/X-ray" title="X-ray">X-ray</a> as "punched-out lesions" (pepper pot skull). <a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">Magnetic resonance imaging</a> (MRI) is more sensitive than simple X-ray in the detection of lytic lesions, and may supersede skeletal survey, especially when <a href="/wiki/Vertebral" title="Vertebral" class="mw-redirect">vertebral</a> disease is suspected. Occasionally a <a href="/wiki/CT_scan" title="CT scan" class="mw-redirect">CT scan</a> is performed to measure the size of soft tissue plasmacytomas. <a href="/wiki/Bone_scan" title="Bone scan" class="mw-redirect">Bone scans</a> are typically not of any additional value in the workup of myeloma patients (no new bone formation; lytic lesions not well visualized on bone scan).</p>
<p>A <a href="/wiki/Bone_marrow_biopsy" title="Bone marrow biopsy" class="mw-redirect">bone marrow biopsy</a> is usually performed to estimate the percentage of bone marrow occupied by plasma cells. This percentage is used in the <a href="/wiki/Diagnostic_criteria" title="Diagnostic criteria" class="mw-redirect">diagnostic criteria</a> for myeloma. <a href="/wiki/Immunohistochemistry" title="Immunohistochemistry">Immunohistochemistry</a> (staining particular cell types using antibodies against surface proteins) can detect plasma cells which express immunoglobulin in the cytoplasm and occasionally on the cell surface; myeloma cells are typically <a href="/wiki/CD56" title="CD56" class="mw-redirect">CD56</a>, <a href="/wiki/CD38" title="CD38">CD38</a>, <a href="/wiki/CD138" title="CD138" class="mw-redirect">CD138</a> positive and <a href="/wiki/CD19" title="CD19">CD19</a> and <a href="/wiki/CD45" title="CD45" class="mw-redirect">CD45</a> negative.<sup class="Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (March 2012)">citation needed</span></a></i>]</sup><sup id="cite_ref-IMWG_2-1" class="reference"><a href="#cite_note-IMWG-2"><span>[</span>2<span>]</span></a></sup> <a href="/wiki/Cytogenetics" title="Cytogenetics">Cytogenetics</a> may also be performed in myeloma for prognostic purposes, including a myeloma-specific <a href="/wiki/Fluorescent_in_situ_hybridization" title="Fluorescent in situ hybridization" class="mw-redirect">FISH</a> and <a href="/wiki/Virtual_Karyotype" title="Virtual Karyotype" class="mw-redirect">Virtual Karyotype</a>.</p>
<p>Other useful laboratory tests include quantitative measurement of <a href="/wiki/IgA" title="IgA" class="mw-redirect">IgA</a>, <a href="/wiki/IgG" title="IgG" class="mw-redirect">IgG</a>, <a href="/wiki/IgM" title="IgM" class="mw-redirect">IgM</a> (<a href="/wiki/Immunoglobulin" title="Immunoglobulin" class="mw-redirect">immunoglobulins</a>) to look for immune paresis, and <a href="/wiki/Beta-2_microglobulin" title="Beta-2 microglobulin">beta-2 microglobulin</a> which provides prognostic information. On peripheral blood smear the <a href="/wiki/Rouleaux" title="Rouleaux">rouleaux</a> formation of <a href="/wiki/Red_blood_cells" title="Red blood cells" class="mw-redirect">red blood cells</a> is commonly seen, though this is not specific.</p>
<p>The recent introduction of a commercial immunoassay for measurement of free light chains potentially offers an improvement in monitoring disease progression and response to treatment, particularly where the paraprotein is difficult to measure accurately by <a href="/wiki/Electrophoresis" title="Electrophoresis">electrophoresis</a> (for example in light chain myeloma, or where the paraprotein level is very low). Initial research also suggests that measurement of free light chains may also be used, in conjunction with other markers, for assessment of the risk of progression from <a href="/wiki/Monoclonal_gammopathy_of_undetermined_significance" title="Monoclonal gammopathy of undetermined significance">monoclonal gammopathy of undetermined significance</a> (MGUS) to multiple myeloma.<sup class="Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (February 2007)">citation needed</span></a></i>]</sup></p>
<p>This assay, the serum free light chain assay, has recently been recommended by the <a href="/wiki/International_Myeloma_Working_Group" title="International Myeloma Working Group" class="mw-redirect">International Myeloma Working Group</a> for the screening, <a href="/wiki/Diagnosis" title="Diagnosis">diagnosis</a>, <a href="/wiki/Prognosis" title="Prognosis">prognosis</a>, and monitoring of plasma cell <a href="/wiki/Dyscrasia" title="Dyscrasia">dyscrasias</a>.</p>
<p>The prognosis of myeloma varies widely depending upon various risk factors. The Mayo Clinic has developed a risk-stratification model termed Mayo Stratification for Myeloma and Risk-adapted Therapy (mSMART) which divides patients into high-risk and standard-risk categories. Patients with deletion of <a href="/wiki/Chromosome_13" title="Chromosome 13" class="mw-redirect">chromosome 13</a> or hypodiploidy by conventional cytogenetics, t(4;14), t(14;16) or <a href="/wiki/Chromosome_17_(human)" title="Chromosome 17 (human)">17p</a>- by molecular genetic studies, or with a high plasma cell labeling index (3% or more) are considered to have high-risk myeloma.</p>
<h3><span class="mw-headline" id="Diagnostic_criteria">Diagnostic criteria</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=10" title="Edit section: Diagnostic criteria">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In 2003, the <a href="/wiki/International_Myeloma_Working_Group" title="International Myeloma Working Group" class="mw-redirect">International Myeloma Working Group</a><sup id="cite_ref-IMWG_2-2" class="reference"><a href="#cite_note-IMWG-2"><span>[</span>2<span>]</span></a></sup> agreed on diagnostic criteria for symptomatic myeloma, asymptomatic myeloma and <a href="/wiki/Monoclonal_gammopathy_of_undetermined_significance" title="Monoclonal gammopathy of undetermined significance">MGUS</a> (monoclonal gammopathy of undetermined significance), which was subsequently updated in 2009:<sup id="cite_ref-7" class="reference"><a href="#cite_note-7"><span>[</span>7<span>]</span></a></sup></p>
<ul>
<li>Symptomatic myeloma:
<ol>
<li>Clonal plasma cells &gt;10% on <a href="/wiki/Bone_marrow" title="Bone marrow">bone marrow</a> <a href="/wiki/Biopsy" title="Biopsy">biopsy</a> or (in any quantity) in a biopsy from other tissues (<a href="/wiki/Plasmacytoma" title="Plasmacytoma">plasmacytoma</a>)</li>
<li>A <a href="/wiki/Monoclonal" title="Monoclonal">monoclonal</a> protein (<a href="/wiki/Paraprotein" title="Paraprotein">paraprotein</a>) in either <a href="/wiki/Blood_plasma" title="Blood plasma">serum</a> or <a href="/wiki/Urine" title="Urine">urine</a> (except in cases of true non-secretory myeloma)</li>
<li>Evidence of end-organ damage felt related to the plasma cell disorder (<i>related organ or tissue impairment</i>, ROTI, commonly referred to by the acronym "CRAB"):
<ul>
<li><a href="/wiki/Hypercalcemia" title="Hypercalcemia" class="mw-redirect">Hyper<b>C</b>alcemia</a> (corrected calcium &gt;2.75&#160;mmol/L)</li>
<li><a href="/wiki/Renal_failure" title="Renal failure"><b>R</b>enal insufficiency</a> attributable to myeloma</li>
<li><a href="/wiki/Anemia" title="Anemia"><b>A</b>nemia</a> (hemoglobin &lt;10 g/dL)</li>
<li><b>B</b>one <a href="/wiki/Lesions" title="Lesions" class="mw-redirect">lesions</a> (lytic lesions or <a href="/wiki/Osteoporosis" title="Osteoporosis">osteoporosis</a> with compression fractures)</li>
</ul>
</li>
</ol>
</li>
</ul>
<p>Note: Recurrent infections alone in a patient who has none of the CRAB features is not sufficient to make the diagnosis of myeloma. Patients who lack CRAB features but have evidence of amyloidosis should be considered as amyloidosis and not myeloma. CRAB like abnormalities are common with numerous diseases, and it is imperative that these abnormalities are felt to be directly attributable to the related plasma cell disorder and every attempt made to rule out other underlying causes of anemia, renal failure etc.</p>
<ul>
<li>Asymptomatic /<a href="/wiki/Smouldering_myeloma" title="Smouldering myeloma">smouldering myeloma</a>:
<ol>
<li>Serum paraprotein &gt;30 g/L AND/OR</li>
<li>Clonal plasma cells &gt;10% on bone marrow biopsy AND</li>
<li>NO myeloma-related organ or tissue impairment</li>
</ol>
</li>
<li>Monoclonal gammopathy of undetermined significance (MGUS):
<ol>
<li>Serum paraprotein &lt;30 g/L AND</li>
<li>Clonal plasma cells &lt;10% on bone marrow biopsy AND</li>
<li>NO myeloma-related organ or tissue impairment</li>
</ol>
</li>
</ul>
<p>Related conditions include <i>solitary <a href="/wiki/Plasmacytoma" title="Plasmacytoma">plasmacytoma</a></i> (a single tumor of plasma cells, typically treated with <a href="/wiki/Irradiation" title="Irradiation">irradiation</a>), <i>plasma cell <a href="/wiki/Dyscrasia" title="Dyscrasia">dyscrasia</a></i> (where only the antibodies produce symptoms, e.g. <a href="/wiki/AL_amyloidosis" title="AL amyloidosis">AL amyloidosis</a>), and <a href="/wiki/POEMS_syndrome" title="POEMS syndrome">POEMS syndrome</a> (peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes).</p>
<h3><span class="mw-headline" id="Staging">Staging</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=11" title="Edit section: Staging">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<dl>
<dt>International Staging System</dt>
</dl>
<p>The International Staging System (ISS) for myeloma was published by the <a href="/wiki/International_Myeloma_Working_Group" title="International Myeloma Working Group" class="mw-redirect">International Myeloma Working Group</a> in 2005:<sup id="cite_ref-ISS_8-0" class="reference"><a href="#cite_note-ISS-8"><span>[</span>8<span>]</span></a></sup></p>
<ul>
<li>Stage I: <a href="/wiki/Beta-2_microglobulin" title="Beta-2 microglobulin">β<sub>2</sub> microglobulin</a> (β2M) &lt; 3.5&#160;mg/L, <a href="/wiki/Serum_albumin" title="Serum albumin">albumin</a> ≥ 3.5 g/dL</li>
<li>Stage II: β2M &lt; 3.5&#160;mg/L and albumin &lt; 3.5&#160;g/dL; or β2M 3.5–5.5&#160;mg/L irrespective of the serum albumin</li>
<li>Stage III: β2M ≥ 5.5&#160;mg/L</li>
</ul>
<p>Note that the ISS should be used only in patients who meet diagnostic criteria for myeloma. Patients with MGUS and asymptomatic myeloma who have renal dysfunction from unrelated causes such as diabetes or hypertension may have elevated β2M levels from the renal dysfunction and cannot be considered as stage III myeloma. This is one of the limitations of the ISS. It does not really quantify tumor burden or extent unlike staging systems used in other cancers. It is more of a prognostic index rather than a true staging system. For this reason, it is recommended that the ISS be used along with the Durie-Salmon Staging System (see below).</p>
<dl>
<dt>Durie-Salmon staging system</dt>
</dl>
<p>First published in 1975, the Durie-Salmon staging system<sup id="cite_ref-Salmon_9-0" class="reference"><a href="#cite_note-Salmon-9"><span>[</span>9<span>]</span></a></sup> is still in use. However, one of the limitations of the Durie-Salmon staging system is the subjectivity in determining the extent of bone disease.</p>
<ul>
<li>stage I: all of
<ul>
<li>Hb &gt; 10g/dL</li>
<li>normal calcium</li>
<li>Skeletal survey: normal or single plasmacytoma or osteoporosis</li>
<li>Serum paraprotein level &lt; 5 g/dL if IgG, &lt; 3 g/dL if IgA</li>
<li>Urinary light chain excretion &lt; 4 g/24h</li>
</ul>
</li>
<li>stage II: fulfilling the criteria of neither I nor III</li>
<li>stage III: one or more of
<ul>
<li>Hb &lt; 8.5g/dL</li>
<li>high calcium &gt; 12&#160;mg/dL</li>
<li>Skeletal survey: Three or more lytic bone lesions</li>
<li>Serum paraprotein &gt; 7g/dL if IgG, &gt; 5 g/dL if IgA</li>
<li>Urinary light chain excretion &gt; 12g/24h</li>
</ul>
</li>
</ul>
<p>Stages I, II, and III of the Durie-Salmon staging system can be divided into A or B depending on serum creatinine:</p>
<ul>
<li>A: serum creatinine &lt; 2&#160;mg/dL (&lt; 177 μmol/L)</li>
<li>B: serum creatinine &gt; 2&#160;mg/dL (&gt; 177 μmol/L)</li>
</ul>
<h2><span class="mw-headline" id="Pathophysiology">Pathophysiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=12" title="Edit section: Pathophysiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p><a href="/wiki/B_lymphocytes" title="B lymphocytes" class="mw-redirect">B lymphocytes</a> start in the bone marrow and move to the lymph nodes. As they progress, they mature and display different proteins on their cell surface. When they are activated to secrete antibodies, they are known as plasma cells.</p>
<p>Multiple myeloma develops in <a href="/wiki/B_lymphocytes" title="B lymphocytes" class="mw-redirect">B lymphocytes</a> after they have left the part of the lymph node known as the <a href="/wiki/Germinal_center" title="Germinal center">germinal center</a>. The normal cell line most closely associated with MM cells is generally taken to be either an activated <a href="/wiki/Memory_B_cell" title="Memory B cell">memory B cell</a> or the precursor to plasma cells, the <a href="/wiki/Plasmablast" title="Plasmablast" class="mw-redirect">plasmablast</a>.<sup id="cite_ref-isbn3-8055-6460-0_10-0" class="reference"><a href="#cite_note-isbn3-8055-6460-0-10"><span>[</span>10<span>]</span></a></sup></p>
<p>The immune system keeps the proliferation of B cells and the secretion of antibodies under tight control. When chromosomes and genes are damaged, often through rearrangement, this control is lost. Often, a promoter gene moves (or translocates) to a chromosome where it stimulates an antibody gene to overproduction.</p>
<p>A <a href="/wiki/Chromosomal_translocation" title="Chromosomal translocation">chromosomal translocation</a> between the immunoglobulin <a href="/wiki/Heavy_chain" title="Heavy chain">heavy chain</a> gene (on <a href="/wiki/Chromosome_14" title="Chromosome 14" class="mw-redirect">chromosome 14</a>, locus q32) and an <a href="/wiki/Oncogene" title="Oncogene">oncogene</a> (often 11q13, 4p16.3, 6p21, 16q23 and 20q11<sup id="cite_ref-Kyle_11-0" class="reference"><a href="#cite_note-Kyle-11"><span>[</span>11<span>]</span></a></sup>) is frequently observed in patients with multiple myeloma. This mutation results in dysregulation of the oncogene which is thought to be an important initiating event in the pathogenesis of myeloma. The result is proliferation of a plasma cell clone and genomic instability that leads to further mutations and translocations. The chromosome 14 abnormality is observed in about 50% of all cases of myeloma. Deletion of (parts of) chromosome 13 is also observed in about 50% of cases.</p>
<p>Production of <a href="/wiki/Cytokine" title="Cytokine">cytokines</a><sup id="cite_ref-Tricot_12-0" class="reference"><a href="#cite_note-Tricot-12"><span>[</span>12<span>]</span></a></sup> (especially <a href="/wiki/Interleukin_6" title="Interleukin 6">IL-6</a>) by the plasma cells causes much of their localised damage, such as <a href="/wiki/Osteoporosis" title="Osteoporosis">osteoporosis</a>, and creates a microenvironment in which the malignant cells thrive. <a href="/wiki/Angiogenesis" title="Angiogenesis">Angiogenesis</a> (the attraction of new blood vessels) is increased.</p>
<p>The produced antibodies are deposited in various organs, leading to renal failure, polyneuropathy and various other myeloma-associated symptoms.</p>
<h2><span class="mw-headline" id="Treatment">Treatment</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=13" title="Edit section: Treatment">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Treatment for multiple myeloma is focused on therapies that decrease the clonal plasma cell population and consequently decrease the signs and symptoms of disease. If the disease is completely asymptomatic (i.e. there is a paraprotein and an abnormal bone marrow population but no end-organ damage), as in smoldering myeloma, treatment is typically deferred, or restricted to clinical trials.<sup id="cite_ref-pmid21441462_13-0" class="reference"><a href="#cite_note-pmid21441462-13"><span>[</span>13<span>]</span></a></sup></p>
<p>In addition to direct treatment of the plasma cell proliferation, <a href="/wiki/Bisphosphonate" title="Bisphosphonate">bisphosphonates</a> (e.g. <a href="/wiki/Pamidronate" title="Pamidronate" class="mw-redirect">pamidronate</a> or <a href="/wiki/Zoledronic_acid" title="Zoledronic acid">zoledronic acid</a>) are routinely administered to prevent fractures; they have also been observed to have direct anti-tumor effect even in patients without known skeletal disease. If needed, <a href="/wiki/Red_blood_cell" title="Red blood cell">red blood cell</a> transfusions or <a href="/wiki/Erythropoietin" title="Erythropoietin">erythropoietin</a> can be used for management of anemia.</p>
<h3><span class="mw-headline" id="Initial_therapy">Initial therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=14" title="Edit section: Initial therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Initial treatment of multiple myeloma depends on the patient’s age and comorbidities. In recent years, high-dose chemotherapy with <a href="/wiki/Hematopoietic_stem_cell_transplantation" title="Hematopoietic stem cell transplantation">autologous hematopoietic stem-cell transplantation</a> has become the preferred treatment for patients under the age of 65. Prior to stem-cell transplantation, these patients receive an initial course of induction chemotherapy. The most common induction regimens used today are <a href="/wiki/Thalidomide" title="Thalidomide">thalidomide</a>–<a href="/wiki/Dexamethasone" title="Dexamethasone">dexamethasone</a>, <a href="/wiki/Bortezomib" title="Bortezomib">bortezomib</a> based regimens, and <a href="/wiki/Lenalidomide" title="Lenalidomide">lenalidomide</a>–dexamethasone.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-15" class="reference"><a href="#cite_note-15"><span>[</span>15<span>]</span></a></sup> <a href="/wiki/Autologous_stem_cell_transplantation" title="Autologous stem cell transplantation">Autologous stem cell transplantation</a> (ASCT), the transplantation of a patient’s own stem cells after chemotherapy, is the most common type of stem cell transplantation for multiple myeloma. It is not curative, but does prolong overall survival and complete remission. <a href="/wiki/Allogeneic_stem_cell_transplantation" title="Allogeneic stem cell transplantation" class="mw-redirect">Allogeneic stem cell transplantation</a>, the transplantation of a healthy person’s stem cells into the affected patient, has the potential for a cure, but is only available to a small percentage of patients.<sup id="cite_ref-Kyle_11-1" class="reference"><a href="#cite_note-Kyle-11"><span>[</span>11<span>]</span></a></sup> Furthermore, there is a 5–10% treatment-associated mortality rate.</p>
<p>Patients over age 65 and patients with significant concurrent illness often cannot tolerate stem cell transplantation. For these patients, the standard of care has been chemotherapy with <a href="/wiki/Melphalan" title="Melphalan">melphalan</a> and prednisone. Recent studies among this population<sup id="cite_ref-Miguel2008_16-0" class="reference"><a href="#cite_note-Miguel2008-16"><span>[</span>16<span>]</span></a></sup> suggest improved outcomes with new chemotherapy regimens, e.g. with <a href="/wiki/Bortezomib" title="Bortezomib">bortezomib</a>.<sup id="cite_ref-Curran2009_17-0" class="reference"><a href="#cite_note-Curran2009-17"><span>[</span>17<span>]</span></a></sup> Treatment with bortezomib, melphalan, and prednisone had an estimated overall survival of 83% at 30 months, lenalidomide plus low-dose dexamethasone an 82% survival at 2 years and melphalan, prednisone and lenalidomide had a 90% survival at 2 years. Head-to-head studies comparing these regimens have not been performed.<sup id="cite_ref-Durie2008_18-0" class="reference"><a href="#cite_note-Durie2008-18"><span>[</span>18<span>]</span></a></sup></p>
<p>A 2009 review noted "Deep venous thrombosis and pulmonary embolism are the major side effects of thalidomide and lenalidomide. Lenalidomide causes more myelosuppression, and thalidomide causes more sedation. <a href="/wiki/Chemotherapy-induced_peripheral_neuropathy" title="Chemotherapy-induced peripheral neuropathy">Chemotherapy-induced peripheral neuropathy</a> and thrombocytopenia are major side effects of bortezomib."<sup id="cite_ref-Abraham2009_19-0" class="reference"><a href="#cite_note-Abraham2009-19"><span>[</span>19<span>]</span></a></sup></p>
<p>Treatment of related <a href="/wiki/Hyperviscosity_syndrome" title="Hyperviscosity syndrome">hyperviscosity syndrome</a> may be required to prevent neurologic symptoms or <a href="/wiki/Renal_failure" title="Renal failure">renal failure</a>.<sup id="cite_ref-Johnson1990_20-0" class="reference"><a href="#cite_note-Johnson1990-20"><span>[</span>20<span>]</span></a></sup><sup id="cite_ref-21" class="reference"><a href="#cite_note-21"><span>[</span>21<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Maintenance_therapy">Maintenance therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=15" title="Edit section: Maintenance therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Sometimes after the initial treatment an ongoing maintenance therapy is offered. A 2009 review of maintenance therapy concluded "In younger patients, post-ASCT maintenance therapy with <a href="/wiki/Thalidomide" title="Thalidomide">thalidomide</a> appears to increase tumor burden reduction further, which translates in[to] prolonged PFS (<a href="/wiki/Progression-free_survival" title="Progression-free survival">Progression-free survival</a>)."<sup id="cite_ref-22" class="reference"><a href="#cite_note-22"><span>[</span>22<span>]</span></a></sup></p>
<p>In 2009 maintenance therapy with thalidomide, lenalidomide, or bortezomib was still of questionable benefit.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23"><span>[</span>23<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Relapse">Relapse</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=16" title="Edit section: Relapse">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The natural history of myeloma is of relapse following treatment. This may be attributed to <a href="/wiki/Tumour_heterogeneity" title="Tumour heterogeneity">tumour heterogeneity</a>. Depending on the patient's condition, the prior treatment modalities used and the duration of remission, options for relapsed disease include re-treatment with the original agent, use of other agents (such as melphalan, cyclophosphamide, thalidomide or dexamethasone, alone or in combination), and a second autologous stem cell transplant.</p>
<p>Later in the course of the disease, "treatment resistance" occurs. This may be a reversible effect,<sup id="cite_ref-Kyle_11-2" class="reference"><a href="#cite_note-Kyle-11"><span>[</span>11<span>]</span></a></sup> and some new treatment modalities may re-sensitize the tumor to standard therapy. For patients with <i>relapsed disease</i>, <a href="/wiki/Bortezomib" title="Bortezomib">bortezomib</a> is a recent addition to the therapeutic arsenal, especially as second line therapy, since 2005. Bortezomib is a <a href="/wiki/Proteasome" title="Proteasome">proteasome</a> inhibitor. Also, <a href="/wiki/Lenalidomide" title="Lenalidomide">lenalidomide</a> (Revlimid), a less toxic thalidomide analog, is showing promise for treating myeloma. The newly approved thalidomide derivative <a href="/wiki/Pomalidomide" title="Pomalidomide">pomalidomide</a> (Pomalyst in the US) may be used for relapsed and refractory multiple myeloma.</p>
<p>More and more patients survive longer and longer, thanks to stem cell transplant (with their own or a donor's) and treatments combining bortezomib (Velcade), dexamethasone and melphalan or cyclophosphamide. This seems to maintain the monoclonal peak at a reasonable level. Survival expectancy is then rising, and new treatments are being developed.</p>
<p>Renal failure in multiple myeloma can be <a href="/wiki/Acute_renal_failure" title="Acute renal failure" class="mw-redirect">acute</a> (reversible) or <a href="/wiki/Chronic_renal_failure" title="Chronic renal failure" class="mw-redirect">chronic</a> (irreversible). Acute renal failure typically resolves when the calcium and paraprotein levels are brought under control. Treatment of chronic renal failure is dependent on the type of renal failure and may involve <a href="/wiki/Dialysis" title="Dialysis">dialysis</a>.</p>
<h2><span class="mw-headline" id="Prognosis">Prognosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=17" title="Edit section: Prognosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>With high-dose therapy followed by <a href="/wiki/Autologous_stem_cell_transplantation" title="Autologous stem cell transplantation">autologous stem cell transplantation</a>, the <a href="/wiki/Median" title="Median">median</a> survival has been estimated in 2003 to be approximately 4.5 years, compared to a median of approximately 3.5 years with "standard" therapy.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24"><span>[</span>24<span>]</span></a></sup> Overall the 5-year survival rate is around 35%.<sup id="cite_ref-MMTMMSR_25-0" class="reference"><a href="#cite_note-MMTMMSR-25"><span>[</span>25<span>]</span></a></sup></p>
<p>The <a href="#Staging">International Staging System</a> can help to predict survival, with a median survival (in 2005) of 62 months for stage 1 disease, 45 months for stage 2 disease, and 29 months for stage 3 disease.<sup id="cite_ref-ISS_8-1" class="reference"><a href="#cite_note-ISS-8"><span>[</span>8<span>]</span></a></sup></p>
<p>The prognoses for patients with multiple myeloma, as those with other diseases, are not the same for everyone. The average age of onset is 70 years. Older patients often are experiencing other serious diseases, which affect survival. Younger patients might have much longer survival rates.</p>
<h3><span class="mw-headline" id="Genetic_testing">Genetic testing</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=18" title="Edit section: Genetic testing">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Some myeloma centers now employ genetic testing, which they call a “gene array.” By examining DNA, oncologists can determine if patients are high risk or low risk of the cancer returning quickly following treatment.</p>
<p><a href="/wiki/Cytogenetic" title="Cytogenetic" class="mw-redirect">Cytogenetic</a> analysis of myeloma cells may be of <a href="/wiki/Prognosis" title="Prognosis">prognostic value</a>, with deletion of chromosome 13, non-hyperdiploidy and the balanced translocations t(4;14) and t(14;16) conferring a poorer prognosis. The 11q13 and 6p21 cytogenetic abnormalities are associated with a better prognosis.</p>
<p>Prognostic markers such as these are always generated by retrospective analyses, and it is likely that new treatment developments will improve the outlook for those with traditionally "poor-risk" disease.</p>
<p><a href="/wiki/Virtual_Karyotype" title="Virtual Karyotype" class="mw-redirect">SNP array karyotyping</a> can detect copy number alterations of prognostic significance that may be missed by a targeted FISH panel.<sup id="cite_ref-pmid19687334_26-0" class="reference"><a href="#cite_note-pmid19687334-26"><span>[</span>26<span>]</span></a></sup> In MM, lack of a proliferative clone makes conventional cytogenetics informative in only ~30% of cases.</p>
<ol>
<li>Virtual karyotyping identified chromosomal abnormalities in 98% of MM cases</li>
<li>del(<a href="/w/index.php?title=12p13.31&amp;action=edit&amp;redlink=1" class="new" title="12p13.31 (page does not exist)">12p13.31</a>) is an independent adverse marker</li>
<li>amp(5q31.1) is a favorable marker</li>
<li>The prognostic impact of amp(5q31.1) over-rides that of hyperdiploidy and also identifies patients who greatly benefit from high-dose therapy.</li>
</ol>
<p><a href="/wiki/Virtual_Karyotype" title="Virtual Karyotype" class="mw-redirect">Array-based karyotyping</a> cannot detect balanced translocations, such as t(4;14) seen in ~15% of MM. Therefore, FISH for this translocation should also be performed if using SNP arrays to detect genome-wide copy number alterations of prognostic significance in MM.</p>
<h2><span class="mw-headline" id="Epidemiology">Epidemiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=19" title="Edit section: Epidemiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Lymphomas,_multiple_myeloma_world_map_-_Death_-_WHO2004.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/dc/Lymphomas%2C_multiple_myeloma_world_map_-_Death_-_WHO2004.svg/220px-Lymphomas%2C_multiple_myeloma_world_map_-_Death_-_WHO2004.svg.png" width="220" height="97" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/dc/Lymphomas%2C_multiple_myeloma_world_map_-_Death_-_WHO2004.svg/330px-Lymphomas%2C_multiple_myeloma_world_map_-_Death_-_WHO2004.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/dc/Lymphomas%2C_multiple_myeloma_world_map_-_Death_-_WHO2004.svg/440px-Lymphomas%2C_multiple_myeloma_world_map_-_Death_-_WHO2004.svg.png 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Lymphomas,_multiple_myeloma_world_map_-_Death_-_WHO2004.svg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf19/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<a href="/wiki/Age_adjustment" title="Age adjustment">Age-standardized</a> death from <a href="/wiki/Lymphomas" title="Lymphomas" class="mw-redirect">lymphomas</a> and multiple myeloma per 100,000&#160;inhabitants in 2004.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27"><span>[</span>27<span>]</span></a></sup>
<div class="references-small" style="-moz-column-count:2; column-count:2;">
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #b3b3b3; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;no data</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffff65; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;less than 1.8</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #fff200; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;1.8–3.6</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffdc00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;3.6–5.4</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffc600; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;5.4–7.2</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ffb000; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;7.2–9</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff9a00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;9–10.8</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff8400; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;10.8–12.6</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff6e00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;12.6–14.4</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff5800; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;14.4–16.2</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff4200; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;16.2–18</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #ff2c00; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;18–19.8</div>
<div class="legend"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #cb0000; color:black; font-size:100%; text-align:center;">&#160;</span>&#160;more than 19.8</div>
</div>
</div>
</div>
</div>
<p>Multiple myeloma, globally, resulted in about 74,000 deaths in 2010 up from 49,000 in 1990.<sup id="cite_ref-Loz2012_28-0" class="reference"><a href="#cite_note-Loz2012-28"><span>[</span>28<span>]</span></a></sup> There are approximately 71,213 people in the <a href="/wiki/United_States" title="United States">United States</a> living with multiple myeloma and according to <a href="/wiki/Surveillance_Epidemiology_and_End_Results" title="Surveillance Epidemiology and End Results" class="mw-redirect">Surveillance Epidemiology and End Results</a> data an estimated 21,700 new cases of myeloma were diagnosed in 2012 in the United States. The age-adjusted incidence rate for multiple myeloma is 5.8 per 100,000 per year.</p>
<p>Multiple myeloma is the second most prevalent blood cancer (10%) after <a href="/wiki/Non-Hodgkin%27s_lymphoma" title="Non-Hodgkin's lymphoma" class="mw-redirect">non-Hodgkin's lymphoma</a>.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29"><span>[</span>29<span>]</span></a></sup> It represents approximately 1% of all cancers and 2% of all cancer deaths. Although the peak age of onset of multiple myeloma is 65 to 70 years of age, recent statistics<sup class="Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (July 2010)">citation needed</span></a></i>]</sup> indicate both increasing incidence and earlier age of onset.</p>
<p>Multiple myeloma affects slightly more men than women. African Americans and Native Pacific Islanders have the highest reported incidence of this disease in the United States and Asians the lowest. Results of a recent study found the incidence of myeloma to be 9.5 cases per 100,000 African Americans and 4.1 cases per 100,000 Caucasian Americans. Among African Americans, myeloma is one of the top 10 leading causes of cancer death.</p>
<p>A familial predisposition to myeloma exists.<sup id="cite_ref-Koura2013_30-0" class="reference"><a href="#cite_note-Koura2013-30"><span>[</span>30<span>]</span></a></sup> Hyperphosphorylation of a number of proteins - the paratarg proteins - a tendency which is inherited in an autosomal dominant manner appears a common mechanism in these families. This tendency is more common in African American patients with myeloma and may contribute to the higher rates of myeloma in this group.<sup id="cite_ref-Koura2013_30-1" class="reference"><a href="#cite_note-Koura2013-30"><span>[</span>30<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Other_animals">Other animals</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=20" title="Edit section: Other animals">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Multiple myeloma affects many other species. The disease has been diagnosed in dogs,<sup id="cite_ref-ettinger_31-0" class="reference"><a href="#cite_note-ettinger-31"><span>[</span>31<span>]</span></a></sup> cats, and horses.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32"><span>[</span>32<span>]</span></a></sup></p>
<p>In dogs, multiple myeloma accounts for around 8% of all haemopoietic tumors. Multiple myeloma occurs in older dogs, and is not particularly associated with either males or females. No breeds appear over represented in case reviews that have been conducted.<sup id="cite_ref-Matus_33-0" class="reference"><a href="#cite_note-Matus-33"><span>[</span>33<span>]</span></a></sup> Diagnosis in dogs is usually delayed due to the initial non specificity and range of clinical signs possible. Diagnosis usually involves bone marrow studies, X-rays, and plasma protein studies. In dogs, protein studies usually reveal the monoclonal gammaglobulin elevation to be IgA or IgG in equal incidence.<sup id="cite_ref-Matus_33-1" class="reference"><a href="#cite_note-Matus-33"><span>[</span>33<span>]</span></a></sup> In rare cases the globulin elevation is IgM, which is referred to as <a href="/wiki/Waldenstr%C3%B6m%27s_macroglobulinemia" title="Waldenström's macroglobulinemia">Waldenström's macroglobulinemia</a>.<sup id="cite_ref-MacEwan_34-0" class="reference"><a href="#cite_note-MacEwan-34"><span>[</span>34<span>]</span></a></sup> The prognosis for initial control and return to good quality of life in dogs is good. 43% of dogs started on a combination chemotheraputic protocol achieved complete remission. Long term survival is normal with a median of 540 days reported.<sup id="cite_ref-Matus_33-2" class="reference"><a href="#cite_note-Matus-33"><span>[</span>33<span>]</span></a></sup> Recurrence is expected eventually, and although rescue protocols can be attempted, recurrences are often resistant to available chemotherapeutics, and death commonly eventually follows from complications such as renal failure, sepsis or pain related owner initiated euthanasia.</p>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=21" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="div-col columns column-count column-count-2" style="-moz-column-count: 2; -webkit-column-count: 2; column-count: 2;">
<ul>
<li><a href="/wiki/Development_of_analogs_of_thalidomide" title="Development of analogs of thalidomide">Development of analogs of thalidomide</a></li>
<li><a href="/wiki/Waldenstr%C3%B6m_macroglobulinemia" title="Waldenström macroglobulinemia" class="mw-redirect">Waldenström macroglobulinemia</a></li>
<li><a href="/wiki/Plasma_cell_leukemia" title="Plasma cell leukemia">Plasma cell leukemia</a>, an aggressive form of MM</li>
<li><a href="/wiki/Multiple_Myeloma_Research_Consortium" title="Multiple Myeloma Research Consortium">Multiple Myeloma Research Consortium</a></li>
<li><a href="/wiki/Multiple_Myeloma_Research_Foundation" title="Multiple Myeloma Research Foundation">Multiple Myeloma Research Foundation</a></li>
<li><a href="/wiki/International_Myeloma_Foundation" title="International Myeloma Foundation">International Myeloma Foundation</a></li>
<li><a href="/wiki/Virtual_Karyotype" title="Virtual Karyotype" class="mw-redirect">Virtual Karyotype</a></li>
</ul>
</div>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=22" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-count references-column-count-2" style="-moz-column-count: 2; -webkit-column-count: 2; column-count: 2; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-Raab-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-Raab_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Raab_1-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Raab_1-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Raab_1-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (July 2009). "Multiple myeloma". <i>Lancet</i> <b>374</b> (9686): 324–39. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0140-6736%2809%2960221-X">10.1016/S0140-6736(09)60221-X</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19541364">19541364</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Multiple+myeloma&amp;rft.aulast=Raab+MS%2C+Podar+K%2C+Breitkreutz+I%2C+Richardson+PG%2C+Anderson+KC&amp;rft.au=Raab+MS%2C+Podar+K%2C+Breitkreutz+I%2C+Richardson+PG%2C+Anderson+KC&amp;rft.date=July+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2809%2960221-X&amp;rft_id=info%3Apmid%2F19541364&amp;rft.issue=9686&amp;rft.jtitle=Lancet&amp;rft.pages=324%E2%80%9339&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=374" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-IMWG-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-IMWG_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-IMWG_2-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-IMWG_2-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">International Myeloma Working Group (2003). "Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group". <i>Br. J. Haematol.</i> <b>121</b> (5): 749–57. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1046%2Fj.1365-2141.2003.04355.x">10.1046/j.1365-2141.2003.04355.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12780789">12780789</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Criteria+for+the+classification+of+monoclonal+gammopathies%2C+multiple+myeloma+and+related+disorders%3A+a+report+of+the+International+Myeloma+Working+Group&amp;rft.au=International+Myeloma+Working+Group&amp;rft.aulast=International+Myeloma+Working+Group&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1046%2Fj.1365-2141.2003.04355.x&amp;rft_id=info%3Apmid%2F12780789&amp;rft.issue=5&amp;rft.jtitle=Br.+J.+Haematol.&amp;rft.pages=749%E2%80%9357&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=121" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text"><span class="citation book">Longo, Dan (2012). <i>Harrison's Principles of Internal Medicine 18th Edition</i>. Mc Graw Hill Medical. p.&#160;938. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-07-174889-6" title="Special:BookSources/978-0-07-174889-6">978-0-07-174889-6</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.aufirst=Dan&amp;rft.aulast=Longo&amp;rft.au=Longo%2C+Dan&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine+18th+Edition&amp;rft.date=2012&amp;rft.genre=book&amp;rft.isbn=978-0-07-174889-6&amp;rft.pages=938&amp;rft.pub=Mc+Graw+Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid8033429-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid8033429_4-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Chapel HM, Lee M (1994). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1550368">"The use of intravenous immune globulin in multiple myeloma"</a>. <i>Clin. Exp. Immunol.</i> <b>97</b> (Suppl 1): 21–4. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1550368">1550368</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8033429">8033429</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=The+use+of+intravenous+immune+globulin+in+multiple+myeloma&amp;rft.au=Chapel+HM%2C+Lee+M&amp;rft.aulast=Chapel+HM%2C+Lee+M&amp;rft.date=1994&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1550368&amp;rft_id=info%3Apmc%2F1550368&amp;rft_id=info%3Apmid%2F8033429&amp;rft.issue=Suppl+1&amp;rft.jtitle=Clin.+Exp.+Immunol.&amp;rft.pages=21%E2%80%934&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=97" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid7730490-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid7730490_5-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Hargreaves RM, Lea JR, Griffiths H, <i>et al.</i> (1995). <a rel="nofollow" class="external text" href="http://jcp.bmj.com/cgi/reprint/48/3/260">"Immunological factors and risk of infection in plateau phase myeloma (stable phase)"</a> (PDF). <i>J. Clin. Pathol.</i> <b>48</b> (3): 260–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1136%2Fjcp.48.3.260">10.1136/jcp.48.3.260</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC502468">502468</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7730490">7730490</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Immunological+factors+and+risk+of+infection+in+plateau+phase+myeloma+%28stable+phase%29&amp;rft.au=Hargreaves+RM%2C+Lea+JR%2C+Griffiths+H%2C+%27%27et+al.%27%27&amp;rft.aulast=Hargreaves+RM%2C+Lea+JR%2C+Griffiths+H%2C+%27%27et+al.%27%27&amp;rft.date=1995&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjcp.bmj.com%2Fcgi%2Freprint%2F48%2F3%2F260&amp;rft_id=info%3Adoi%2F10.1136%2Fjcp.48.3.260&amp;rft_id=info%3Apmc%2F502468&amp;rft_id=info%3Apmid%2F7730490&amp;rft.issue=3&amp;rft.jtitle=J.+Clin.+Pathol.&amp;rft.pages=260%E2%80%936&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=48" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Robbins-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-Robbins_6-0">^</a></b></span> <span class="reference-text"><span class="citation book">Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson. "Multiple myeloma". <i>Robbins Basic Pathology</i> (8th ed.). Philadelphia: Saunders. p.&#160;455. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/1-4160-2973-7" title="Special:BookSources/1-4160-2973-7">1-4160-2973-7</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Robbins+Basic+Pathology&amp;rft.aulast=Mitchell%2C+Richard+Sheppard%3B+Kumar%2C+Vinay%3B+Abbas%2C+Abul+K.%3B+Fausto%2C+Nelson&amp;rft.au=Mitchell%2C+Richard+Sheppard%3B+Kumar%2C+Vinay%3B+Abbas%2C+Abul+K.%3B+Fausto%2C+Nelson&amp;rft.btitle=Multiple+myeloma&amp;rft.edition=8th&amp;rft.genre=bookitem&amp;rft.isbn=1-4160-2973-7&amp;rft.pages=455&amp;rft.place=Philadelphia&amp;rft.pub=Saunders&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><span class="citation journal">Kyle RA, Rajkumar SV (January 2009). <a rel="nofollow" class="external text" href="http://www.nature.com/leu/journal/v23/n1/full/leu2008291a.html">"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma"</a>. <i>Leukemia</i> <b>23</b> (1): 3–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1038%2Fleu.2008.291">10.1038/leu.2008.291</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2627786">2627786</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18971951">18971951</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Criteria+for+diagnosis%2C+staging%2C+risk+stratification+and+response+assessment+of+multiple+myeloma&amp;rft.au=Kyle+RA%2C+Rajkumar+SV&amp;rft.aulast=Kyle+RA%2C+Rajkumar+SV&amp;rft.date=January+2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.nature.com%2Fleu%2Fjournal%2Fv23%2Fn1%2Ffull%2Fleu2008291a.html&amp;rft_id=info%3Adoi%2F10.1038%2Fleu.2008.291&amp;rft_id=info%3Apmc%2F2627786&amp;rft_id=info%3Apmid%2F18971951&amp;rft.issue=1&amp;rft.jtitle=Leukemia&amp;rft.pages=3%E2%80%939&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=23" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-ISS-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-ISS_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-ISS_8-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Greipp PR, San Miguel J, Durie BG, <i>et al.</i> (2005). <a rel="nofollow" class="external text" href="http://jco.ascopubs.org/cgi/content/full/23/15/3412">"International staging system for multiple myeloma"</a>. <i>J. Clin. Oncol.</i> <b>23</b> (15): 3412–20. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1200%2FJCO.2005.04.242">10.1200/JCO.2005.04.242</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15809451">15809451</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=International+staging+system+for+multiple+myeloma&amp;rft.au=Greipp+PR%2C+San+Miguel+J%2C+Durie+BG%2C+%27%27et+al.%27%27&amp;rft.aulast=Greipp+PR%2C+San+Miguel+J%2C+Durie+BG%2C+%27%27et+al.%27%27&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Ffull%2F23%2F15%2F3412&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2005.04.242&amp;rft_id=info%3Apmid%2F15809451&amp;rft.issue=15&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=3412%E2%80%9320&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=23" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Salmon-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-Salmon_9-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Durie BG, Salmon SE (1975). "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival". <i>Cancer</i> <b>36</b> (3): 842–54. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F1097-0142%28197509%2936%3A3%3C842%3A%3AAID-CNCR2820360303%3E3.0.CO%3B2-U">10.1002/1097-0142(197509)36:3&lt;842::AID-CNCR2820360303&gt;3.0.CO;2-U</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/1182674">1182674</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=A+clinical+staging+system+for+multiple+myeloma.+Correlation+of+measured+myeloma+cell+mass+with+presenting+clinical+features%2C+response+to+treatment%2C+and+survival&amp;rft.au=Durie+BG%2C+Salmon+SE&amp;rft.aulast=Durie+BG%2C+Salmon+SE&amp;rft.date=1975&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F1097-0142%28197509%2936%3A3%3C842%3A%3AAID-CNCR2820360303%3E3.0.CO%3B2-U&amp;rft_id=info%3Apmid%2F1182674&amp;rft.issue=3&amp;rft.jtitle=Cancer&amp;rft.pages=842%E2%80%9354&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=36" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-isbn3-8055-6460-0-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-isbn3-8055-6460-0_10-0">^</a></b></span> <span class="reference-text"><span class="citation book">Federico Caligaris-Cappio; Manlio Ferrarini (1997). <a rel="nofollow" class="external text" href="http://books.google.com.au/books?id=1Oj7GLSeDpYC&amp;pg=PA104"><i>Human B Cell Populations</i></a>. Chemical Immunology <b>67</b>. Switzerland: S. Karger AG. p.&#160;105. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/3-8055-6460-0" title="Special:BookSources/3-8055-6460-0">3-8055-6460-0</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.au=Federico+Caligaris-Cappio%3B+Manlio+Ferrarini&amp;rft.aulast=Federico+Caligaris-Cappio%3B+Manlio+Ferrarini&amp;rft.btitle=Human+B+Cell+Populations&amp;rft.date=1997&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fbooks.google.com.au%2Fbooks%3Fid%3D1Oj7GLSeDpYC%26pg%3DPA104&amp;rft.isbn=3-8055-6460-0&amp;rft.pages=105&amp;rft.place=Switzerland&amp;rft.pub=S.+Karger+AG&amp;rft.series=Chemical+Immunology&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.volume=67" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Kyle-11"><span class="mw-cite-backlink">^ <a href="#cite_ref-Kyle_11-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Kyle_11-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Kyle_11-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Kyle RA, Rajkumar SV (2004). "Multiple myeloma". <i>N. Engl. J. Med.</i> <b>351</b> (18): 1860–73. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1056%2FNEJMra041875">10.1056/NEJMra041875</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15509819">15509819</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Multiple+myeloma&amp;rft.au=Kyle+RA%2C+Rajkumar+SV&amp;rft.aulast=Kyle+RA%2C+Rajkumar+SV&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMra041875&amp;rft_id=info%3Apmid%2F15509819&amp;rft.issue=18&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=1860%E2%80%9373&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=351" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Tricot-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-Tricot_12-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Tricot G (2000). "New insights into role of microenvironment in multiple myeloma.". <i>Lancet</i> <b>355</b> (9200): 248–50. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0140-6736%2800%2900019-2">10.1016/S0140-6736(00)00019-2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10675068">10675068</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=New+insights+into+role+of+microenvironment+in+multiple+myeloma.&amp;rft.aulast=Tricot+G&amp;rft.au=Tricot+G&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2800%2900019-2&amp;rft_id=info%3Apmid%2F10675068&amp;rft.issue=9200&amp;rft.jtitle=Lancet&amp;rft.pages=248%E2%80%9350&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=355" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid21441462-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid21441462_13-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Korde N, Kristinsson SY, Landgren O (2011). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/content/117/21/5573.long">"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies"</a>. <i><a href="/wiki/Blood_(journal)" title="Blood (journal)">Blood (journal)</a></i> <b>117</b> (21): 5573–5581. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1182%2Fblood-2011-01-270140">10.1182/blood-2011-01-270140</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3316455">3316455</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21441462">21441462</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Monoclonal+gammopathy+of+undetermined+significance+%28MGUS%29+and+smoldering+multiple+myeloma+%28SMM%29%3A+novel+biological+insights+and+development+of+early+treatment+strategies&amp;rft.au=Korde+N%2C+Kristinsson+SY%2C+Landgren+O&amp;rft.aulast=Korde+N%2C+Kristinsson+SY%2C+Landgren+O&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcontent%2F117%2F21%2F5573.long&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2011-01-270140&amp;rft_id=info%3Apmc%2F3316455&amp;rft_id=info%3Apmid%2F21441462&amp;rft.issue=21&amp;rft.jtitle=Blood+%28journal%29&amp;rft.pages=5573%E2%80%935581&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=117" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><span class="citation journal">Kyle, R.A., Rajkumar, S.V. (2008). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/111/6/2962#F4">"Multiple myeloma"</a>. <i>Blood.</i> <b>111</b> (6): 2962–72. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1182%2Fblood-2007-10-078022">10.1182/blood-2007-10-078022</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2265446">2265446</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18332230">18332230</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Multiple+myeloma&amp;rft.au=Kyle%2C+R.A.%2C+Rajkumar%2C+S.V.&amp;rft.aulast=Kyle%2C+R.A.%2C+Rajkumar%2C+S.V.&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F111%2F6%2F2962%23F4&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2007-10-078022&amp;rft_id=info%3Apmc%2F2265446&amp;rft_id=info%3Apmid%2F18332230&amp;rft.issue=6&amp;rft.jtitle=Blood.&amp;rft.pages=2962%E2%80%9372&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=111" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://hemonc.org/Multiple_myeloma">Multiple myeloma chemotherapy regimens</a></span></li>
<li id="cite_note-Miguel2008-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-Miguel2008_16-0">^</a></b></span> <span class="reference-text"><span class="citation journal">San Miguel, J.F. et al. (2008). "Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma". <i>N. Engl. J. Med.</i> <b>359</b> (9): 906–917. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1056%2FNEJMoa0801479">10.1056/NEJMoa0801479</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18753647">18753647</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Bortezomib+plus+Melphalan+and+Prednisone+for+Initial+Treatment+of+Multiple+Myeloma&amp;rft.aulast=San+Miguel%2C+J.F.+et+al.&amp;rft.au=San+Miguel%2C+J.F.+et+al.&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa0801479&amp;rft_id=info%3Apmid%2F18753647&amp;rft.issue=9&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=906%E2%80%93917&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=359" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Curran2009-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-Curran2009_17-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Curran M, McKeage K. (2009). <a rel="nofollow" class="external text" href="http://adisonline.com/drugs/abstract/2009/69070/Bortezomib__A_Review_of_its_Use_in_Patients_with.6.aspx">"Bortezomib: A Review of its Use in Patients with Multiple Myeloma"</a>. <i>Drugs</i> <b>69</b> (7): 859–888. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.2165%2F00003495-200969070-00006">10.2165/00003495-200969070-00006</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19441872">19441872</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Bortezomib%3A+A+Review+of+its+Use+in+Patients+with+Multiple+Myeloma&amp;rft.au=Curran+M%2C+McKeage+K.&amp;rft.aulast=Curran+M%2C+McKeage+K.&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fadisonline.com%2Fdrugs%2Fabstract%2F2009%2F69070%2FBortezomib__A_Review_of_its_Use_in_Patients_with.6.aspx&amp;rft_id=info%3Adoi%2F10.2165%2F00003495-200969070-00006&amp;rft_id=info%3Apmid%2F19441872&amp;rft.issue=7&amp;rft.jtitle=Drugs&amp;rft.pages=859%E2%80%93888&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=69" class="Z3988"><span style="display:none;">&#160;</span></span> <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.2165%2F00003495-200969070-00006">10.2165/00003495-200969070-00006</a>.</span></li>
<li id="cite_note-Durie2008-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-Durie2008_18-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Durie, B.G.M. (2008). "Treatment of Myeloma — Are We Making Progress?". <i>N. Engl. J. Med.</i> <b>359</b> (9): 964–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1056%2FNEJMe0805176">10.1056/NEJMe0805176</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18753654">18753654</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Treatment+of+Myeloma+%E2%80%94+Are+We+Making+Progress%3F&amp;rft.au=Durie%2C+B.G.M.&amp;rft.aulast=Durie%2C+B.G.M.&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMe0805176&amp;rft_id=info%3Apmid%2F18753654&amp;rft.issue=9&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=964%E2%80%936&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=359" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Abraham2009-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-Abraham2009_19-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Abraham J (2009). <a rel="nofollow" class="external text" href="http://www.communityoncology.net/journal/articles/0602053.pdf">"Advances in multiple myeloma treatment: lenalidomide and bortezomib"</a> (PDF). <i>Community Oncology</i> <b>6</b> (2): 53. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS1548-5315%2811%2970208-X">10.1016/S1548-5315(11)70208-X</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Advances+in+multiple+myeloma+treatment%3A+lenalidomide+and+bortezomib&amp;rft.au=Abraham+J&amp;rft.aulast=Abraham+J&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.communityoncology.net%2Fjournal%2Farticles%2F0602053.pdf&amp;rft_id=info%3Adoi%2F10.1016%2FS1548-5315%2811%2970208-X&amp;rft.issue=2&amp;rft.jtitle=Community+Oncology&amp;rft.pages=53&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Johnson1990-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-Johnson1990_20-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE (April 1990). <a rel="nofollow" class="external text" href="http://archinte.ama-assn.org/cgi/pmidlookup?view=long&amp;pmid=2183734">"Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy"</a>. <i>Arch. Intern. Med.</i> <b>150</b> (4): 863–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1001%2Farchinte.1990.00390160111022">10.1001/archinte.1990.00390160111022</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2183734">2183734</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Treatment+of+renal+failure+associated+with+multiple+myeloma.+Plasmapheresis%2C+hemodialysis%2C+and+chemotherapy&amp;rft.au=Johnson+WJ%2C+Kyle+RA%2C+Pineda+AA%2C+O%27Brien+PC%2C+Holley+KE&amp;rft.aulast=Johnson+WJ%2C+Kyle+RA%2C+Pineda+AA%2C+O%27Brien+PC%2C+Holley+KE&amp;rft.date=April+1990&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Farchinte.ama-assn.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D2183734&amp;rft_id=info%3Adoi%2F10.1001%2Farchinte.1990.00390160111022&amp;rft_id=info%3Apmid%2F2183734&amp;rft.issue=4&amp;rft.jtitle=Arch.+Intern.+Med.&amp;rft.pages=863%E2%80%939&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=150" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><span class="citation journal">Paul M, Walker F, Bear RA (November 1982). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1862296">"Plasmapheresis therapy in a patient with multiple myeloma"</a>. <i>Can Med Assoc J</i> <b>127</b> (10): 956. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1862296">1862296</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7139441">7139441</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Plasmapheresis+therapy+in+a+patient+with+multiple+myeloma&amp;rft.aulast=Paul+M%2C+Walker+F%2C+Bear+RA&amp;rft.au=Paul+M%2C+Walker+F%2C+Bear+RA&amp;rft.date=November+1982&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1862296&amp;rft_id=info%3Apmc%2F1862296&amp;rft_id=info%3Apmid%2F7139441&amp;rft.issue=10&amp;rft.jtitle=Can+Med+Assoc+J&amp;rft.pages=956&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=127" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><span class="citation journal">Harousseau J.-L. (2009). <a rel="nofollow" class="external text" href="http://pagepress.org/journals/index.php/hr/article/view/hr.2009.e12/1247">"Maintenance therapy in multiple myeloma"</a>. <i>Hematology Reviews</i> <b>1</b> (2): e12. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.4081%2Fhr.2009.e12">10.4081/hr.2009.e12</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Maintenance+therapy+in+multiple+myeloma&amp;rft.au=Harousseau+J.-L.&amp;rft.aulast=Harousseau+J.-L.&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fpagepress.org%2Fjournals%2Findex.php%2Fhr%2Farticle%2Fview%2Fhr.2009.e12%2F1247&amp;rft_id=info%3Adoi%2F10.4081%2Fhr.2009.e12&amp;rft.issue=2&amp;rft.jtitle=Hematology+Reviews&amp;rft.pages=e12&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=1" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><span class="citation journal"><a rel="nofollow" class="external text" href="http://www.communityoncology.net/journal/articles/0602053.pdf">"Managing the side effects of lenalidomide and bortezomib"</a> (PDF). <i>Community Oncology</i>: 58. 2009.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Managing+the+side+effects+of+lenalidomide+and+bortezomib&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.communityoncology.net%2Fjournal%2Farticles%2F0602053.pdf&amp;rft.jtitle=Community+Oncology&amp;rft.pages=58&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><span class="citation journal">Child JA, Morgan GJ, Davies FE, <i>et al.</i> (May 2003). "High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma". <i>N. Engl. J. Med.</i> <b>348</b> (19): 1875–83. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1056%2FNEJMoa022340">10.1056/NEJMoa022340</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12736280">12736280</a>. [<a rel="nofollow" class="external text" href="http://www.medscape.com/viewarticle/472098_2">Stem Cell Transplantation for Multiple Myeloma: High-Dose Therapy and Stem Cell Transplantation</a> Lay summary] – <i>Medscape</i>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=High-dose+chemotherapy+with+hematopoietic+stem-cell+rescue+for+multiple+myeloma&amp;rft.au=Child+JA%2C+Morgan+GJ%2C+Davies+FE%2C+%27%27et+al.%27%27&amp;rft.aulast=Child+JA%2C+Morgan+GJ%2C+Davies+FE%2C+%27%27et+al.%27%27&amp;rft.date=May+2003&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa022340&amp;rft_id=info%3Apmid%2F12736280&amp;rft.issue=19&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=1875%E2%80%9383&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=348" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-MMTMMSR-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-MMTMMSR_25-0">^</a></b></span> <span class="reference-text"><span class="citation web">Seiter, K; Shah, D; Chansky, HA; Gellman, H; Grethlein, SJ; Krishnan, K; Rizvi, SS; Schmitz, MA; Talavera, F; Thomas, LM (23 December 2013). <a rel="nofollow" class="external text" href="http://emedicine.medscape.com/article/204369-overview#showall">"Multiple Myeloma Treatment &amp; Management"</a>. In Besa, EC. <i>Medscape Reference</i>. WebMD<span class="reference-accessdate">. Retrieved 2 January 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Multiple+Myeloma+Treatment+%26+Management&amp;rft.aulast=Seiter%2C+K%3B+Shah%2C+D%3B+Chansky%2C+HA%3B+Gellman%2C+H%3B+Grethlein%2C+SJ%3B+Krishnan%2C+K%3B+Rizvi%2C+SS%3B+Schmitz%2C+MA%3B+Talavera%2C+F%3B+Thomas%2C+LM&amp;rft.au=Seiter%2C+K%3B+Shah%2C+D%3B+Chansky%2C+HA%3B+Gellman%2C+H%3B+Grethlein%2C+SJ%3B+Krishnan%2C+K%3B+Rizvi%2C+SS%3B+Schmitz%2C+MA%3B+Talavera%2C+F%3B+Thomas%2C+LM&amp;rft.date=23+December+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Femedicine.medscape.com%2Farticle%2F204369-overview%23showall&amp;rft.jtitle=Medscape+Reference&amp;rft.pub=WebMD&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid19687334-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid19687334_26-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Avet-Loiseau H, Li C, Magrangeas F, <i>et al.</i> (September 2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2754906">"Prognostic significance of copy-number alterations in multiple myeloma"</a>. <i>J. Clin. Oncol.</i> <b>27</b> (27): 4585–90. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1200%2FJCO.2008.20.6136">10.1200/JCO.2008.20.6136</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2754906">2754906</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19687334">19687334</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Prognostic+significance+of+copy-number+alterations+in+multiple+myeloma&amp;rft.au=Avet-Loiseau+H%2C+Li+C%2C+Magrangeas+F%2C+%27%27et+al.%27%27&amp;rft.aulast=Avet-Loiseau+H%2C+Li+C%2C+Magrangeas+F%2C+%27%27et+al.%27%27&amp;rft.date=September+2009&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2754906&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2008.20.6136&amp;rft_id=info%3Apmc%2F2754906&amp;rft_id=info%3Apmid%2F19687334&amp;rft.issue=27&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=4585%E2%80%9390&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=27" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/index.html">"WHO Disease and injury country estimates"</a>. <i>World Health Organization</i>. 2009<span class="reference-accessdate">. Retrieved Nov 11, 2009</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=WHO+Disease+and+injury+country+estimates&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.who.int%2Fhealthinfo%2Fglobal_burden_disease%2Festimates_country%2Fen%2Findex.html&amp;rft.jtitle=World+Health+Organization&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Loz2012-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-Loz2012_28-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lozano, R (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.". <i>Lancet</i> <b>380</b> (9859): 2095–128. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0140-6736%2812%2961728-0">10.1016/S0140-6736(12)61728-0</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23245604">23245604</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Global+and+regional+mortality+from+235+causes+of+death+for+20+age+groups+in+1990+and+2010%3A+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2010.&amp;rft.aufirst=R&amp;rft.aulast=Lozano&amp;rft.au=Lozano%2C+R&amp;rft.date=Dec+15%2C+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2812%2961728-0&amp;rft_id=info%3Apmid%2F23245604&amp;rft.issue=9859&amp;rft.jtitle=Lancet&amp;rft.pages=2095%E2%80%93128&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=380" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><span class="citation journal">Collins CD (2005). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1665317">"Problems monitoring response in multiple myeloma"</a>. <i>Cancer Imaging</i> <b>5</b> (Spec No A): S119–26. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1102%2F1470-7330.2005.0033">10.1102/1470-7330.2005.0033</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1665317">1665317</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16361127">16361127</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Problems+monitoring+response+in+multiple+myeloma&amp;rft.au=Collins+CD&amp;rft.aulast=Collins+CD&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1665317&amp;rft_id=info%3Adoi%2F10.1102%2F1470-7330.2005.0033&amp;rft_id=info%3Apmc%2F1665317&amp;rft_id=info%3Apmid%2F16361127&amp;rft.issue=Spec+No+A&amp;rft.jtitle=Cancer+Imaging&amp;rft.pages=S119%E2%80%9326&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=5" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Koura2013-30"><span class="mw-cite-backlink">^ <a href="#cite_ref-Koura2013_30-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Koura2013_30-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Koura DT, Langston AA (August 2013). "Inherited predisposition to multiple myeloma". <i>Ther Adv Hematol</i> <b>4</b> (4): 291–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1177%2F2040620713485375">10.1177/2040620713485375</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23926460">23926460</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Inherited+predisposition+to+multiple+myeloma&amp;rft.au=Koura+DT%2C+Langston+AA&amp;rft.aulast=Koura+DT%2C+Langston+AA&amp;rft.date=August+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1177%2F2040620713485375&amp;rft_id=info%3Apmid%2F23926460&amp;rft.issue=4&amp;rft.jtitle=Ther+Adv+Hematol&amp;rft.pages=291%E2%80%937&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-ettinger-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-ettinger_31-0">^</a></b></span> <span class="reference-text"><span class="citation book">Ettinger, Stephen J.; Feldman, Edward C. (1 June 2000). <i>Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat</i> <b>1</b>. W.B. Saunders. pp.&#160;516–9. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-7216-7257-1" title="Special:BookSources/978-0-7216-7257-1">978-0-7216-7257-1</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.au=Ettinger%2C+Stephen+J.&amp;rft.au=Feldman%2C+Edward+C.&amp;rft.aufirst=Stephen+J.&amp;rft.aulast=Ettinger&amp;rft.btitle=Textbook+of+Veterinary+Internal+Medicine%3A+Diseases+of+the+Dog+and+Cat&amp;rft.date=1+June+2000&amp;rft.genre=book&amp;rft.isbn=978-0-7216-7257-1&amp;rft.pages=516%E2%80%939&amp;rft.pub=W.B.+Saunders&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.volume=1" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><span class="citation journal">MacAllister C, Qualls C, Tyler R, Root CR (August 1987). "Multiple myeloma in a horse". <i>J. Am. Vet. Med. Assoc.</i> <b>191</b> (3): 337–9. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3654300">3654300</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Multiple+myeloma+in+a+horse&amp;rft.aulast=MacAllister+C%2C+Qualls+C%2C+Tyler+R%2C+Root+CR&amp;rft.au=MacAllister+C%2C+Qualls+C%2C+Tyler+R%2C+Root+CR&amp;rft.date=August+1987&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F3654300&amp;rft.issue=3&amp;rft.jtitle=J.+Am.+Vet.+Med.+Assoc.&amp;rft.pages=337%E2%80%939&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=191" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Matus-33"><span class="mw-cite-backlink">^ <a href="#cite_ref-Matus_33-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Matus_33-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Matus_33-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Matus, R.E.; Leifer, C.E.; MacEwen, E.G.; Hurvitz, A.I. (1986). "Prognostic factors for multiple myeloma in the dog". <i>J Am Vet Med Assoc</i> <b>11</b> (188): 1288–92. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3721983">3721983</a></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Prognostic+factors+for+multiple+myeloma+in+the+dog&amp;rft.aufirst=R.E.&amp;rft.au=Hurvitz%2C+A.I.&amp;rft.aulast=Matus&amp;rft.au=Leifer%2C+C.E.&amp;rft.au=MacEwen%2C+E.G.&amp;rft.au=Matus%2C+R.E.&amp;rft.date=1986&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F3721983&amp;rft.issue=188&amp;rft.jtitle=J+Am+Vet+Med+Assoc&amp;rft.pages=1288%E2%80%9392&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=11" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-MacEwan-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-MacEwan_34-0">^</a></b></span> <span class="reference-text"><span class="citation journal">MacEwan, E.G.; Hurvitz, A.I. (1977). "Diagnosis and Management of Monoclonal Gammopathies". <i>Vet Clin North American Small Animal Practice</i> <b>7</b>: 119</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMultiple+myeloma&amp;rft.atitle=Diagnosis+and+Management+of+Monoclonal+Gammopathies&amp;rft.aufirst=E.G.&amp;rft.au=Hurvitz%2C+A.I.&amp;rft.aulast=MacEwan&amp;rft.au=MacEwan%2C+E.G.&amp;rft.date=1977&amp;rft.genre=article&amp;rft.jtitle=Vet+Clin+North+American+Small+Animal+Practice&amp;rft.pages=119&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit&amp;section=23" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a rel="nofollow" class="external text" href="http://www.dmoz.org/Health/Conditions_and_Diseases/Cancer/Hematologic/Multiple_Myeloma/">Multiple myeloma</a> on the <a href="/wiki/Open_Directory_Project" title="Open Directory Project">Open Directory Project</a></li>
</ul>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2" style="background:Silver;">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Immunoproliferative_immunoglobulin_disorders" title="Template:Immunoproliferative immunoglobulin disorders"><span title="View this template" style=";background:Silver;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Immunoproliferative_immunoglobulin_disorders" title="Template talk:Immunoproliferative immunoglobulin disorders"><span title="Discuss this template" style=";background:Silver;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Immunoproliferative_immunoglobulin_disorders&amp;action=edit"><span title="Edit this template" style=";background:Silver;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;"><a href="/wiki/Immune_disorder" title="Immune disorder">Immune disorders</a>, <a href="/wiki/Immunoproliferative_disorder" title="Immunoproliferative disorder">Immunoproliferative</a> <a href="/wiki/Antibody" title="Antibody">immunoglobulin</a> disorders (<a href="/wiki/ICD-10_Chapter_III:_Diseases_of_the_blood_and_blood-forming_organs,_and_certain_disorders_involving_the_immune_mechanism#.28D80.E2.80.93D89.29_Certain_disorders_involving_the_immune_mechanism" title="ICD-10 Chapter III: Diseases of the blood and blood-forming organs, and certain disorders involving the immune mechanism">D89</a>, <a href="/wiki/List_of_ICD-9_codes_240%E2%80%93279:_endocrine,_nutritional_and_metabolic_diseases,_and_immunity_disorders" title="List of ICD-9 codes 240–279: endocrine, nutritional and metabolic diseases, and immunity disorders">273</a>)</div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGreen;"><a href="/wiki/Plasma_cell_dyscrasia" title="Plasma cell dyscrasia">PCDs</a>/<a href="/wiki/Paraproteinemia" title="Paraproteinemia">PP</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Plasmacytoma" title="Plasmacytoma">Plasmacytoma</a></li>
<li><strong class="selflink">Multiple myeloma</strong> (<a href="/wiki/Plasma_cell_leukemia" title="Plasma cell leukemia">Plasma cell leukemia</a>)</li>
<li><a href="/wiki/Monoclonal_gammopathy_of_undetermined_significance" title="Monoclonal gammopathy of undetermined significance">MGUS</a></li>
<li><i><a href="/wiki/Immunoglobulin_M" title="Immunoglobulin M">IgM</a></i> (<a href="/wiki/Macroglobulinemia" title="Macroglobulinemia">Macroglobulinemia</a>/<a href="/wiki/Waldenstr%C3%B6m%27s_macroglobulinemia" title="Waldenström's macroglobulinemia">Waldenström's macroglobulinemia</a>)</li>
<li><i><a href="/wiki/Immunoglobulin_heavy_chain" title="Immunoglobulin heavy chain">heavy chain</a></i> (<a href="/wiki/Heavy_chain_disease" title="Heavy chain disease">Heavy chain disease</a>)</li>
<li><i><a href="/wiki/Immunoglobulin_light_chain" title="Immunoglobulin light chain">light chain</a></i> (<a href="/wiki/AL_amyloidosis" title="AL amyloidosis">Primary amyloidosis</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGreen;">Other <a href="/wiki/Hypergammaglobulinemia" title="Hypergammaglobulinemia">hypergammaglobulinemia</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Cryoglobulinemia" title="Cryoglobulinemia">Cryoglobulinemia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;;">
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;background:transparent;color:inherit;;">
<div style="padding:0px;;">
<table cellspacing="0" class="navbox-columns-table" style="text-align:left;width:100%;">
<tr style="vertical-align:top;">
<td style="padding:0px;text-align:center;background:#efefef;;;text-align:center;background:LightGreen;;width:10em;">
<div>
<p><a href="/wiki/Template:Medicine_navs" title="Template:Medicine navs">M</a>: <a href="/wiki/Lymphocyte" title="Lymphocyte">LMC</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:white;;width:10em;">
<div>
<p><a href="/wiki/Template:Lymphocytes" title="Template:Lymphocytes">cell</a>/<a href="/wiki/Template:Lymphocytic_immune_system" title="Template:Lymphocytic immune system">phys</a>/<a href="/wiki/Template:Autoantigens" title="Template:Autoantigens">auag</a>/<a href="/wiki/Template:Autoantibodies" title="Template:Autoantibodies">auab</a>/<a href="/wiki/Template:Complement_system" title="Template:Complement system">comp</a>, <a href="/wiki/Template:Immunoglobulin_superfamily_immune_receptors" title="Template:Immunoglobulin superfamily immune receptors">igrc</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:silver;;width:10em;">
<div>
<p><a href="/wiki/Template:Lymphoid_and_complement_immunodeficiency" title="Template:Lymphoid and complement immunodeficiency">imdf</a>/<a href="/wiki/Template:Immunoproliferative_immunoglobulin_disorders" title="Template:Immunoproliferative immunoglobulin disorders">ipig</a>/<a href="/wiki/Template:Hypersensitivity_and_autoimmune_diseases" title="Template:Hypersensitivity and autoimmune diseases">hyps</a>/<a href="/wiki/Template:Lymphoid_malignancy" title="Template:Lymphoid malignancy">tumr</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:#ccf;;width:10em;">
<div>
<p><a href="/wiki/Template:Immunologic_techniques_and_tests" title="Template:Immunologic techniques and tests">proc</a>, drug (<a href="/wiki/Template:Immunostimulants" title="Template:Immunostimulants">L3</a>/<a href="/wiki/Template:Immunosuppressants" title="Template:Immunosuppressants">4</a>)</p>
</div>
</td>
</tr>
</table>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2" style="background:Silver;">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Lymphoid_malignancy" title="Template:Lymphoid malignancy"><span title="View this template" style=";background:Silver;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Lymphoid_malignancy" title="Template talk:Lymphoid malignancy"><span title="Discuss this template" style=";background:Silver;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Lymphoid_malignancy&amp;action=edit"><span title="Edit this template" style=";background:Silver;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;"><a href="/wiki/Hematological_malignancy" title="Hematological malignancy">Hematological malignancy</a>/<a href="/wiki/Leukemia" title="Leukemia">leukemia</a> histology (<a href="/wiki/International_Classification_of_Diseases_for_Oncology#.289590.E2.80.939999.29_Hematologic_.28Leukemias.2C_Lymphomas_and_related_disorders.29" title="International Classification of Diseases for Oncology">ICD-O 9590–9989</a>, <a href="/wiki/ICD-10_Chapter_II:_Neoplasms#.28C81.E2.80.93C96.29_Malignant_neoplasms.2C_stated_or_presumed_to_be_primary.2C_of_lymphoid.2C_haematopoietic_and_related_tissue" title="ICD-10 Chapter II: Neoplasms">C81–C96</a>, <a href="/wiki/List_of_ICD-9_codes_140%E2%80%93239:_neoplasms#Malignant_neoplasm_of_lymphatic_and_hematopoietic_tissue_.28200.E2.80.93208.29" title="List of ICD-9 codes 140–239: neoplasms">200–208</a>)<br />
<a href="/wiki/Lymphocyte" title="Lymphocyte">Lymphoid</a>/<a href="/wiki/Lymphoproliferative_disorders" title="Lymphoproliferative disorders">Lymphoproliferative</a>, <a href="/wiki/Lymphoma" title="Lymphoma">Lymphomas</a>/<a href="/wiki/Lymphoid_leukemia" title="Lymphoid leukemia">Lymphoid leukemias</a> (9590–9739, 9800–9839)</div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/Lymphoma#Mature_B_cell_neoplasms" title="Lymphoma">B cell</a><br />
(<a href="/wiki/B-cell_lymphoma" title="B-cell lymphoma">lymphoma</a>,<br />
<a href="/wiki/B-cell_leukemia" title="B-cell leukemia">leukemia</a>)<br />
(most <a href="/wiki/CD19" title="CD19">CD19</a>
<ul>
<li><a href="/wiki/CD20" title="CD20">CD20</a>)</li>
</ul>
</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;">By development/<br />
marker</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/Terminal_deoxynucleotidyl_transferase" title="Terminal deoxynucleotidyl transferase">TdT+</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Acute_lymphoblastic_leukemia" title="Acute lymphoblastic leukemia">ALL</a> (<a href="/wiki/Precursor_B-cell_lymphoblastic_leukemia" title="Precursor B-cell lymphoblastic leukemia">Precursor B acute lymphoblastic leukemia/lymphoma</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/CD5_(protein)" title="CD5 (protein)">CD5</a>+</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i><a href="/wiki/Naive_B_cell" title="Naive B cell">naive B cell</a></i> (<a href="/wiki/B-cell_chronic_lymphocytic_leukemia" title="B-cell chronic lymphocytic leukemia">CLL/SLL</a>)</li>
</ul>
</div>
<div><i><a href="/wiki/Mantle_zone" title="Mantle zone">mantle zone</a></i> (<a href="/wiki/Mantle_cell_lymphoma" title="Mantle cell lymphoma">Mantle cell</a>)</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/CD22" title="CD22">CD22</a>+</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/B-cell_prolymphocytic_leukemia" title="B-cell prolymphocytic leukemia">Prolymphocytic</a></li>
<li><i><a href="/wiki/CD11c" title="CD11c">CD11c+</a></i> (<a href="/wiki/Hairy_cell_leukemia" title="Hairy cell leukemia">Hairy cell leukemia</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/CD79A" title="CD79A">CD79a</a>+</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i><a href="/wiki/Germinal_center" title="Germinal center">germinal center</a>/<a href="/wiki/Follicular_B_cell" title="Follicular B cell">follicular B cell</a></i> (<a href="/wiki/Follicular_lymphoma" title="Follicular lymphoma">Follicular</a></li>
<li><a href="/wiki/Burkitt%27s_lymphoma" title="Burkitt's lymphoma">Burkitt's</a></li>
<li><a href="/wiki/GCB_DLBCL" title="GCB DLBCL" class="mw-redirect">GCB DLBCL</a></li>
<li><a href="/wiki/Primary_cutaneous_follicular_lymphoma" title="Primary cutaneous follicular lymphoma">Primary cutaneous follicular lymphoma</a>)</li>
</ul>
</div>
<div><i><a href="/wiki/Marginal_zone_B-cell_lymphoma" title="Marginal zone B-cell lymphoma">marginal zone</a>/<a href="/wiki/Marginal-zone_B_cell" title="Marginal-zone B cell" class="mw-redirect">marginal-zone B cell</a></i> (<a href="/wiki/Splenic_marginal_zone_lymphoma" title="Splenic marginal zone lymphoma">Splenic marginal zone</a>
<ul>
<li><a href="/wiki/MALT_lymphoma" title="MALT lymphoma">MALT</a></li>
<li><a href="/wiki/Nodal_marginal_zone_B_cell_lymphoma" title="Nodal marginal zone B cell lymphoma">Nodal marginal zone</a></li>
<li><a href="/wiki/Primary_cutaneous_marginal_zone_lymphoma" title="Primary cutaneous marginal zone lymphoma">Primary cutaneous marginal zone lymphoma</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/Reed-Sternberg_cell" title="Reed-Sternberg cell" class="mw-redirect">RS</a> (<a href="/wiki/CD15" title="CD15">CD15</a>+, <a href="/wiki/CD30" title="CD30">CD30</a>+)</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Hodgkin%27s_lymphoma" title="Hodgkin's lymphoma">Classic Hodgkin's lymphoma</a> (<a href="/wiki/Nodular_sclerosis" title="Nodular sclerosis">Nodular sclerosis</a>)</li>
<li><i><a href="/wiki/CD20" title="CD20">CD20+</a></i> (<a href="/wiki/Nodular_lymphocyte_predominant_Hodgkin%27s_lymphoma" title="Nodular lymphocyte predominant Hodgkin's lymphoma">Nodular lymphocyte predominant Hodgkin's lymphoma</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/Plasma_cell_dyscrasia" title="Plasma cell dyscrasia">PCDs</a>/<a href="/wiki/Paraproteinemia" title="Paraproteinemia">PP</a><br />
(<a href="/wiki/CD38" title="CD38">CD38</a>+/<a href="/wiki/CD138" title="CD138" class="mw-redirect">CD138</a>+)</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>see <a href="/wiki/Template:Immunoproliferative_immunoglobulin_disorders" title="Template:Immunoproliferative immunoglobulin disorders">immunoproliferative immunoglobulin disorders</a></i></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;">By infection</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i><a href="/wiki/Kaposi%27s_sarcoma-associated_herpesvirus" title="Kaposi's sarcoma-associated herpesvirus">KSHV</a></i> (<a href="/wiki/Primary_effusion_lymphoma" title="Primary effusion lymphoma">Primary effusion</a>)</li>
<li><i><a href="/wiki/Epstein-Barr_virus" title="Epstein-Barr virus" class="mw-redirect">EBV</a></i> (<a href="/wiki/Lymphomatoid_granulomatosis" title="Lymphomatoid granulomatosis">Lymphomatoid granulomatosis</a></li>
<li><a href="/wiki/Post-transplant_lymphoproliferative_disorder" title="Post-transplant lymphoproliferative disorder">Post-transplant lymphoproliferative disorder</a>)</li>
<li><i><a href="/wiki/HIV" title="HIV">HIV</a></i> (<a href="/wiki/AIDS-related_lymphoma" title="AIDS-related lymphoma">AIDS-related lymphoma</a>)</li>
<li><i><a href="/wiki/Helicobacter_pylori" title="Helicobacter pylori">Helicobacter pylori</a></i> (<a href="/wiki/MALT_lymphoma" title="MALT lymphoma">MALT lymphoma</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/Cutaneous_B-cell_lymphoma" title="Cutaneous B-cell lymphoma">Cutaneous</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Diffuse_large_B-cell_lymphoma" title="Diffuse large B-cell lymphoma">Diffuse large B-cell lymphoma</a></li>
<li><a href="/wiki/Intravascular_large_B-cell_lymphoma" title="Intravascular large B-cell lymphoma">Intravascular large B-cell lymphoma</a></li>
<li><a href="/wiki/Primary_cutaneous_marginal_zone_lymphoma" title="Primary cutaneous marginal zone lymphoma">Primary cutaneous marginal zone lymphoma</a></li>
<li><a href="/wiki/Primary_cutaneous_immunocytoma" title="Primary cutaneous immunocytoma">Primary cutaneous immunocytoma</a></li>
<li><a href="/wiki/Plasmacytoma" title="Plasmacytoma">Plasmacytoma</a></li>
<li><a href="/wiki/Plasmacytosis" title="Plasmacytosis">Plasmacytosis</a></li>
<li><a href="/wiki/Primary_cutaneous_follicular_lymphoma" title="Primary cutaneous follicular lymphoma">Primary cutaneous follicular lymphoma</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/Lymphoma#Mature_T_cell_and_natural_killer_.28NK.29_cell_neoplasms" title="Lymphoma">T/NK</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/T_cell" title="T cell">T cell</a><br />
(<a href="/wiki/T-cell_lymphoma" title="T-cell lymphoma">lymphoma</a>,<br />
<a href="/wiki/T-cell_leukemia" title="T-cell leukemia">leukemia</a>)<br />
(most <a href="/wiki/CD3_(immunology)" title="CD3 (immunology)">CD3</a>
<ul>
<li><a href="/wiki/CD4" title="CD4">CD4</a></li>
<li><a href="/wiki/CD8" title="CD8">CD8</a>)</li>
</ul>
</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;">By development/<br />
marker</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Terminal_deoxynucleotidyl_transferase" title="Terminal deoxynucleotidyl transferase">TdT+</a>: <a href="/wiki/Acute_lymphoblastic_leukemia" title="Acute lymphoblastic leukemia">ALL</a> (<a href="/wiki/Precursor_T-cell_lymphoblastic_leukemia" title="Precursor T-cell lymphoblastic leukemia">Precursor T acute lymphoblastic leukemia/lymphoma</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/Prolymphocyte" title="Prolymphocyte">prolymphocyte</a></i> (<a href="/wiki/T-cell_prolymphocytic_leukemia" title="T-cell prolymphocytic leukemia">Prolymphocytic</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/CD30" title="CD30">CD30+</a></i> (<a href="/wiki/Anaplastic_large-cell_lymphoma" title="Anaplastic large-cell lymphoma">Anaplastic large-cell lymphoma</a></li>
<li><a href="/wiki/Lymphomatoid_papulosis" title="Lymphomatoid papulosis">Lymphomatoid papulosis type A</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/Cutaneous_T-cell_lymphoma" title="Cutaneous T-cell lymphoma" class="mw-redirect">Cutaneous</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/Mycosis_fungoides" title="Mycosis fungoides">MF+variants</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>indolent:</i> <a href="/wiki/Mycosis_fungoides" title="Mycosis fungoides">Mycosis fungoides</a></li>
<li><a href="/wiki/Pagetoid_reticulosis" title="Pagetoid reticulosis">Pagetoid reticulosis</a></li>
<li><a href="/wiki/Granulomatous_slack_skin" title="Granulomatous slack skin">Granulomatous slack skin</a><br /></li>
</ul>
<p><i>aggressive:</i> <a href="/wiki/S%C3%A9zary%27s_disease" title="Sézary's disease">Sézary's disease</a></p>
<ul>
<li><a href="/wiki/Adult_T-cell_leukemia/lymphoma" title="Adult T-cell leukemia/lymphoma">Adult T-cell leukemia/lymphoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;">Non-MF</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/CD30" title="CD30">CD30</a>-: <a href="/wiki/Non-mycosis_fungoides_CD30%E2%88%92_cutaneous_large_T-cell_lymphoma" title="Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma">Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma</a></li>
<li><a href="/wiki/Pleomorphic_T-cell_lymphoma" title="Pleomorphic T-cell lymphoma">Pleomorphic T-cell lymphoma</a></li>
<li><a href="/wiki/Lymphomatoid_papulosis" title="Lymphomatoid papulosis">Lymphomatoid papulosis type B</a></li>
</ul>
<p><a href="/wiki/CD30" title="CD30">CD30</a>+: <a href="/wiki/CD30%2B_cutaneous_T-cell_lymphoma" title="CD30+ cutaneous T-cell lymphoma">CD30+ cutaneous T-cell lymphoma</a></p>
<ul>
<li><a href="/wiki/Secondary_cutaneous_CD30%2B_large_cell_lymphoma" title="Secondary cutaneous CD30+ large cell lymphoma" class="mw-redirect">Secondary cutaneous CD30+ large cell lymphoma</a></li>
<li><a href="/wiki/Lymphomatoid_papulosis" title="Lymphomatoid papulosis">Lymphomatoid papulosis type A</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;">Other <a href="/wiki/Peripheral_T-cell_lymphoma" title="Peripheral T-cell lymphoma">peripheral</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Hepatosplenic_T-cell_lymphoma" title="Hepatosplenic T-cell lymphoma">Hepatosplenic</a></li>
<li><a href="/wiki/Angioimmunoblastic_T-cell_lymphoma" title="Angioimmunoblastic T-cell lymphoma">Angioimmunoblastic</a></li>
<li><a href="/wiki/Enteropathy-associated_T-cell_lymphoma" title="Enteropathy-associated T-cell lymphoma">Enteropathy-associated T-cell lymphoma</a></li>
<li><a href="/wiki/Peripheral_T-cell_lymphoma-Not-Otherwise-Specified" title="Peripheral T-cell lymphoma-Not-Otherwise-Specified" class="mw-redirect">Peripheral T-cell lymphoma-Not-Otherwise-Specified</a> (<a href="/wiki/Lennert_lymphoma" title="Lennert lymphoma">Lennert lymphoma</a>)</li>
<li><a href="/wiki/Subcutaneous_T-cell_lymphoma" title="Subcutaneous T-cell lymphoma">Subcutaneous T-cell lymphoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;">By infection</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i><a href="/wiki/Human_T-lymphotropic_virus_1" title="Human T-lymphotropic virus 1">HTLV-1</a></i> (<a href="/wiki/Adult_T-cell_leukemia/lymphoma" title="Adult T-cell leukemia/lymphoma">Adult T-cell leukemia/lymphoma</a>)</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/Lymphoma#Mature_T_cell_and_natural_killer_.28NK.29_cell_neoplasms" title="Lymphoma">NK cell</a>/<br />
(most <a href="/wiki/CD56" title="CD56" class="mw-redirect">CD56</a>)</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Aggressive_NK-cell_leukemia" title="Aggressive NK-cell leukemia">Aggressive NK-cell leukemia</a></li>
<li><a href="/wiki/Blastic_NK_cell_lymphoma" title="Blastic NK cell lymphoma">Blastic NK cell lymphoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;">T or NK</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i><a href="/wiki/Epstein-Barr_virus" title="Epstein-Barr virus" class="mw-redirect">EBV</a></i> (<a href="/wiki/Extranodal_NK-T-cell_lymphoma" title="Extranodal NK-T-cell lymphoma" class="mw-redirect">Extranodal NK-T-cell lymphoma</a>/<a href="/wiki/Angiocentric_lymphoma" title="Angiocentric lymphoma">Angiocentric lymphoma</a>)</li>
<li><a href="/wiki/Large_granular_lymphocytic_leukemia" title="Large granular lymphocytic leukemia">Large granular lymphocytic leukemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;">Lymphoid+myeloid</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Acute_biphenotypic_leukaemia" title="Acute biphenotypic leukaemia">Acute biphenotypic leukaemia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;background-color: LightGreen;">
<div style="padding:0em 0.75em;"><a href="/wiki/Lymphocytosis" title="Lymphocytosis">Lymphocytosis</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Lymphoproliferative_disorders" title="Lymphoproliferative disorders">Lymphoproliferative disorders</a> (<a href="/wiki/X-linked_lymphoproliferative_disease" title="X-linked lymphoproliferative disease">X-linked lymphoproliferative disease</a></li>
<li><a href="/wiki/Autoimmune_lymphoproliferative_syndrome" title="Autoimmune lymphoproliferative syndrome">Autoimmune lymphoproliferative syndrome</a>)</li>
<li><a href="/wiki/Leukemoid_reaction" title="Leukemoid reaction">Leukemoid reaction</a></li>
<li><a href="/wiki/Diffuse_infiltrative_lymphocytosis_syndrome" title="Diffuse infiltrative lymphocytosis syndrome">Diffuse infiltrative lymphocytosis syndrome</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGreen;"><a href="/wiki/Cutaneous_lymphoid_hyperplasia" title="Cutaneous lymphoid hyperplasia">Cutaneous lymphoid hyperplasia</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Cutaneous_lymphoid_hyperplasia" title="Cutaneous lymphoid hyperplasia">Cutaneous lymphoid hyperplasia</a>
<ul>
<li><a href="/wiki/Cutaneous_lymphoid_hyperplasia_with_bandlike_and_perivascular_patterns" title="Cutaneous lymphoid hyperplasia with bandlike and perivascular patterns" class="mw-redirect">with bandlike and perivascular patterns</a></li>
<li><a href="/wiki/Cutaneous_lymphoid_hyperplasia_with_nodular_pattern" title="Cutaneous lymphoid hyperplasia with nodular pattern" class="mw-redirect">with nodular pattern</a></li>
</ul>
</li>
<li><a href="/wiki/Jessner_lymphocytic_infiltrate_of_the_skin" title="Jessner lymphocytic infiltrate of the skin" class="mw-redirect">Jessner lymphocytic infiltrate of the skin</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;;">
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;background:transparent;color:inherit;;">
<div style="padding:0px;;">
<table cellspacing="0" class="navbox-columns-table" style="text-align:left;width:100%;">
<tr style="vertical-align:top;">
<td style="padding:0px;text-align:center;background:#efefef;;;text-align:center;background:LightGreen;;width:10em;">
<div>
<p><a href="/wiki/Template:Medicine_navs" title="Template:Medicine navs">M</a>: <a href="/wiki/Lymphocyte" title="Lymphocyte">LMC</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:white;;width:10em;">
<div>
<p><a href="/wiki/Template:Lymphocytes" title="Template:Lymphocytes">cell</a>/<a href="/wiki/Template:Lymphocytic_immune_system" title="Template:Lymphocytic immune system">phys</a>/<a href="/wiki/Template:Autoantigens" title="Template:Autoantigens">auag</a>/<a href="/wiki/Template:Autoantibodies" title="Template:Autoantibodies">auab</a>/<a href="/wiki/Template:Complement_system" title="Template:Complement system">comp</a>, <a href="/wiki/Template:Immunoglobulin_superfamily_immune_receptors" title="Template:Immunoglobulin superfamily immune receptors">igrc</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:silver;;width:10em;">
<div>
<p><a href="/wiki/Template:Lymphoid_and_complement_immunodeficiency" title="Template:Lymphoid and complement immunodeficiency">imdf</a>/<a href="/wiki/Template:Immunoproliferative_immunoglobulin_disorders" title="Template:Immunoproliferative immunoglobulin disorders">ipig</a>/<a href="/wiki/Template:Hypersensitivity_and_autoimmune_diseases" title="Template:Hypersensitivity and autoimmune diseases">hyps</a>/<a href="/wiki/Template:Lymphoid_malignancy" title="Template:Lymphoid malignancy">tumr</a></p>
</div>
</td>
<td style="border-left:2px solid #fdfdfd;padding:0px;text-align:center;background:#efefef;;;text-align:center;background:#ccf;;width:10em;">
<div>
<p><a href="/wiki/Template:Immunologic_techniques_and_tests" title="Template:Immunologic techniques and tests">proc</a>, drug (<a href="/wiki/Template:Immunostimulants" title="Template:Immunostimulants">L3</a>/<a href="/wiki/Template:Immunosuppressants" title="Template:Immunosuppressants">4</a>)</p>
</div>
</td>
</tr>
</table>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2" style="background:Silver;">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Chromosomal_abnormalities" title="Template:Chromosomal abnormalities"><span title="View this template" style=";background:Silver;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Chromosomal_abnormalities" title="Template talk:Chromosomal abnormalities"><span title="Discuss this template" style=";background:Silver;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Chromosomal_abnormalities&amp;action=edit"><span title="Edit this template" style=";background:Silver;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;"><a href="/wiki/Pathology" title="Pathology">Pathology</a>: <a href="/wiki/Chromosome_abnormalities" title="Chromosome abnormalities" class="mw-redirect">chromosome abnormalities</a> (<a href="/wiki/ICD-10_Chapter_Q#Q90.E2.80.93Q99_.E2.80.93_Chromosomal_abnormalities.2C_not_elsewhere_classified" title="ICD-10 Chapter Q" class="mw-redirect">Q90–Q99</a>, <a href="/wiki/List_of_ICD-9_codes_740%E2%80%93759:_congenital_anomalies#Chromosomal_anomalies" title="List of ICD-9 codes 740–759: congenital anomalies">758</a>)</div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;"><a href="/wiki/Autosome" title="Autosome">Autosomal</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;"><a href="/wiki/Trisomy" title="Trisomy">Trisomies</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Down_syndrome" title="Down syndrome">Down syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_21_(human)" title="Chromosome 21 (human)">21</a></li>
</ul>
</li>
<li><a href="/wiki/Edwards_syndrome" title="Edwards syndrome">Edwards syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_18_(human)" title="Chromosome 18 (human)">18</a></li>
</ul>
</li>
<li><a href="/wiki/Patau_syndrome" title="Patau syndrome">Patau syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_13_(human)" title="Chromosome 13 (human)">13</a></li>
</ul>
</li>
</ul>
<ul>
<li><a href="/wiki/Trisomy_9" title="Trisomy 9">Trisomy 9</a></li>
<li><a href="/wiki/Warkany_syndrome_2" title="Warkany syndrome 2" class="mw-redirect">Warkany syndrome 2</a>
<ul>
<li><a href="/wiki/Chromosome_8_(human)" title="Chromosome 8 (human)">8</a></li>
</ul>
</li>
<li><a href="/wiki/Cat_eye_syndrome" title="Cat eye syndrome">Cat eye syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_22_(human)" title="Chromosome 22 (human)">22</a></li>
</ul>
</li>
<li><a href="/wiki/Trisomy_16" title="Trisomy 16">Trisomy 16</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;"><a href="/wiki/Monosomy" title="Monosomy">Monosomies</a>/<a href="/wiki/Deletion_(genetics)" title="Deletion (genetics)">deletions</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/1q21.1_deletion_syndrome" title="1q21.1 deletion syndrome">1q21.1 deletion syndrome</a>/<a href="/wiki/1q21.1_duplication_syndrome" title="1q21.1 duplication syndrome">1q21.1 duplication syndrome</a>/<a href="/wiki/TAR_syndrome" title="TAR syndrome">TAR syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_1_(human)" title="Chromosome 1 (human)">1</a></li>
</ul>
</li>
<li><a href="/wiki/Wolf-Hirschhorn_syndrome" title="Wolf-Hirschhorn syndrome" class="mw-redirect">Wolf-Hirschhorn syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_4_(human)" title="Chromosome 4 (human)">4</a></li>
</ul>
</li>
<li><a href="/wiki/Cri_du_chat" title="Cri du chat">Cri du chat</a>/<a href="/wiki/Chromosome_5q_deletion_syndrome" title="Chromosome 5q deletion syndrome">Chromosome 5q deletion syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_5_(human)" title="Chromosome 5 (human)">5</a></li>
</ul>
</li>
<li><a href="/wiki/Williams_syndrome" title="Williams syndrome">Williams syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_7_(human)" title="Chromosome 7 (human)">7</a></li>
</ul>
</li>
<li><a href="/wiki/Jacobsen_syndrome" title="Jacobsen syndrome">Jacobsen syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_11_(human)" title="Chromosome 11 (human)">11</a></li>
</ul>
</li>
<li><a href="/wiki/Miller%E2%80%93Dieker_syndrome" title="Miller–Dieker syndrome">Miller–Dieker syndrome</a>/<a href="/wiki/Smith%E2%80%93Magenis_syndrome" title="Smith–Magenis syndrome">Smith–Magenis syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_17_(human)" title="Chromosome 17 (human)">17</a></li>
</ul>
</li>
<li><a href="/wiki/DiGeorge_syndrome" title="DiGeorge syndrome">DiGeorge syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_22_(human)" title="Chromosome 22 (human)">22</a></li>
</ul>
</li>
<li><a href="/wiki/22q11.2_distal_deletion_syndrome" title="22q11.2 distal deletion syndrome">22q11.2 distal deletion syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_22_(human)" title="Chromosome 22 (human)">22</a></li>
</ul>
</li>
<li><a href="/wiki/22q13_deletion_syndrome" title="22q13 deletion syndrome">22q13 deletion syndrome</a>
<ul>
<li><a href="/wiki/Chromosome_22_(human)" title="Chromosome 22 (human)">22</a></li>
</ul>
</li>
</ul>
<ul>
<li><i><a href="/wiki/Genomic_imprinting" title="Genomic imprinting">genomic imprinting</a></i>
<ul>
<li><a href="/wiki/Angelman_syndrome" title="Angelman syndrome">Angelman syndrome</a>/<a href="/wiki/Prader%E2%80%93Willi_syndrome" title="Prader–Willi syndrome">Prader–Willi syndrome</a> (<a href="/wiki/Chromosome_15_(human)" title="Chromosome 15 (human)">15</a>)</li>
</ul>
</li>
</ul>
<ul>
<li><a href="/wiki/Distal_18q-" title="Distal 18q-">Distal 18q-</a>/<a href="/wiki/Proximal_18q-" title="Proximal 18q-">Proximal 18q-</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;"><a href="/wiki/X_chromosome" title="X chromosome">X</a>/<a href="/wiki/Y_chromosome" title="Y chromosome">Y</a> linked</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;"><a href="/wiki/Monosomy" title="Monosomy">Monosomy</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Turner_syndrome" title="Turner syndrome">Turner syndrome (XO)</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;"><a href="/wiki/Trisomy" title="Trisomy">Trisomy</a>/<a href="/wiki/Tetrasomy" title="Tetrasomy">tetrasomy</a>,<br />
<a href="/wiki/Aneuploidy" title="Aneuploidy">other karyotypes</a>/<a href="/wiki/Mosaic_(genetics)" title="Mosaic (genetics)">mosaics</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Klinefelter_syndrome" title="Klinefelter syndrome">Klinefelter syndrome (47,XXY)</a></li>
<li><a href="/wiki/XXYY_syndrome" title="XXYY syndrome">48,XXYY</a></li>
<li><a href="/wiki/48,_XXXY" title="48, XXXY" class="mw-redirect">48,XXXY</a></li>
<li><a href="/w/index.php?title=49,_XXXYY&amp;action=edit&amp;redlink=1" class="new" title="49, XXXYY (page does not exist)">49,XXXYY</a></li>
<li><a href="/wiki/49,_XXXXY_syndrome" title="49, XXXXY syndrome">49,XXXXY</a></li>
</ul>
<ul>
<li><a href="/wiki/Triple_X_syndrome" title="Triple X syndrome">Triple X syndrome (47,XXX)</a></li>
<li><a href="/wiki/48,_XXXX" title="48, XXXX">48,XXXX</a></li>
<li><a href="/wiki/49,_XXXXX" title="49, XXXXX">49,XXXXX</a></li>
</ul>
<ul>
<li><a href="/wiki/XYY_syndrome" title="XYY syndrome">47,XYY</a></li>
<li><a href="/w/index.php?title=48,_XYYY&amp;action=edit&amp;redlink=1" class="new" title="48, XYYY (page does not exist)">48,XYYY</a></li>
<li><a href="/w/index.php?title=49,_XYYYY&amp;action=edit&amp;redlink=1" class="new" title="49, XYYYY (page does not exist)">49,XYYYY</a></li>
</ul>
<ul>
<li><a href="/wiki/46,_XX/XY" title="46, XX/XY">46,XX/XY</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;"><a href="/wiki/Chromosomal_translocation" title="Chromosomal translocation">Translocations</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;"><a href="/wiki/Leukemia" title="Leukemia">Leukemia</a>/<a href="/wiki/Lymphoma" title="Lymphoma">lymphoma</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;">Lymphoid</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Burkitt%27s_lymphoma" title="Burkitt's lymphoma">Burkitt's lymphoma</a> t(8 <a href="/wiki/Myc" title="Myc">MYC</a>;14 <a href="/wiki/IGH@" title="IGH@">IGH</a>)</li>
<li><a href="/wiki/Follicular_lymphoma" title="Follicular lymphoma">Follicular lymphoma</a> t(14 <a href="/wiki/IGH@" title="IGH@">IGH</a>;18 <a href="/wiki/Bcl-2" title="Bcl-2">BCL2</a>)</li>
<li><a href="/wiki/Mantle_cell_lymphoma" title="Mantle cell lymphoma">Mantle cell lymphoma</a>/<strong class="selflink">Multiple myeloma</strong> t(11 <a href="/wiki/Cyclin_D1" title="Cyclin D1">CCND1</a>:14 <a href="/wiki/IGH@" title="IGH@">IGH</a>)</li>
<li><a href="/wiki/Anaplastic_large_cell_lymphoma" title="Anaplastic large cell lymphoma" class="mw-redirect">Anaplastic large cell lymphoma</a> t(2 <a href="/wiki/Anaplastic_lymphoma_kinase" title="Anaplastic lymphoma kinase">ALK</a>;5 <a href="/wiki/NPM1" title="NPM1">NPM1</a>)</li>
<li><a href="/wiki/Acute_lymphoblastic_leukemia" title="Acute lymphoblastic leukemia">Acute lymphoblastic leukemia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;">Myeloid</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Philadelphia_chromosome" title="Philadelphia chromosome">Philadelphia chromosome</a> t(9 <a href="/wiki/Abl_gene" title="Abl gene" class="mw-redirect">ABL</a>; 22 <a href="/wiki/BCR_gene" title="BCR gene" class="mw-redirect">BCR</a>)</li>
<li><a href="/wiki/Acute_myeloblastic_leukemia_with_maturation" title="Acute myeloblastic leukemia with maturation">Acute myeloblastic leukemia with maturation</a> t(8 <a href="/wiki/RUNX1T1" title="RUNX1T1">RUNX1T1</a>;21 <a href="/wiki/RUNX1" title="RUNX1">RUNX1</a>)</li>
<li><a href="/wiki/Acute_promyelocytic_leukemia" title="Acute promyelocytic leukemia">Acute promyelocytic leukemia</a> t(15 <a href="/wiki/Promyelocytic_leukemia_protein" title="Promyelocytic leukemia protein">PML</a>,17 <a href="/wiki/Retinoic_acid_receptor_alpha" title="Retinoic acid receptor alpha">RARA</a>)</li>
<li><a href="/wiki/Acute_megakaryoblastic_leukemia" title="Acute megakaryoblastic leukemia">Acute megakaryoblastic leukemia</a> t(1 <a href="/wiki/RBM15" title="RBM15">RBM15</a>;22 <a href="/wiki/MKL1" title="MKL1">MKL1</a>)</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;">Other</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Ewing%27s_sarcoma" title="Ewing's sarcoma">Ewing's sarcoma</a> t(11 <a href="/wiki/FLI1" title="FLI1">FLI1</a>; 22 <a href="/wiki/Ewing_sarcoma_breakpoint_region_1" title="Ewing sarcoma breakpoint region 1">EWS</a>)</li>
<li><a href="/wiki/Synovial_sarcoma" title="Synovial sarcoma">Synovial sarcoma</a> t(x <a href="/wiki/SYT" title="SYT" class="mw-redirect">SYT</a>;18 <a href="/wiki/Synovial_sarcoma,_X_breakpoint" title="Synovial sarcoma, X breakpoint">SSX</a>)</li>
<li><a href="/wiki/Dermatofibrosarcoma_protuberans" title="Dermatofibrosarcoma protuberans">Dermatofibrosarcoma protuberans</a> t(17 <a href="/wiki/Collagen,_type_I,_alpha_1" title="Collagen, type I, alpha 1">COL1A1</a>;22 <a href="/wiki/PDGFB" title="PDGFB">PDGFB</a>)</li>
<li><a href="/wiki/Myxoid_liposarcoma" title="Myxoid liposarcoma">Myxoid liposarcoma</a> t(12 <a href="/wiki/DNA_damage-inducible_transcript_3" title="DNA damage-inducible transcript 3">DDIT3</a>; 16 <a href="/wiki/FUS" title="FUS">FUS</a>)</li>
<li><a href="/wiki/Desmoplastic_small_round_cell_tumor" title="Desmoplastic small round cell tumor" class="mw-redirect">Desmoplastic small round cell tumor</a> t(11 <a href="/wiki/WT1" title="WT1">WT1</a>; 22 <a href="/wiki/Ewing_sarcoma_breakpoint_region_1" title="Ewing sarcoma breakpoint region 1">EWS</a>)</li>
<li><a href="/wiki/Alveolar_rhabdomyosarcoma" title="Alveolar rhabdomyosarcoma">Alveolar rhabdomyosarcoma</a> t(2 <a href="/wiki/PAX3" title="PAX3">PAX3</a>; 13 <a href="/wiki/FOXO1" title="FOXO1">FOXO1</a>) t (1 <a href="/wiki/PAX7" title="PAX7">PAX7</a>; 13 <a href="/wiki/FOXO1" title="FOXO1">FOXO1</a>)</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background-color: LightGray;">Other</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Fragile_X_syndrome" title="Fragile X syndrome">Fragile X syndrome</a></li>
<li><a href="/wiki/Uniparental_disomy" title="Uniparental disomy">Uniparental disomy</a></li>
<li><a href="/wiki/XX_male_syndrome" title="XX male syndrome">XX male syndrome</a></li>
<li><a href="/wiki/Ring_chromosome" title="Ring chromosome">Ring chromosome</a> (13; <a href="/wiki/Ring_chromosome_14_syndrome" title="Ring chromosome 14 syndrome">14</a>; 15; <a href="/wiki/Ring_chromosome_20_syndrome" title="Ring chromosome 20 syndrome">20</a>)</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1005
CPU time usage: 4.352 seconds
Real time usage: 4.517 seconds
Preprocessor visited node count: 6184/1000000
Preprocessor generated node count: 20870/1500000
Post‐expand include size: 301191/2048000 bytes
Template argument size: 30111/2048000 bytes
Highest expansion depth: 20/40
Expensive parser function count: 10/500
Lua time usage: 0.255/10.000 seconds
Lua memory usage: 3.24 MB/50 MB
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:292137-0!*!0!!en!4!* and timestamp 20140328220358
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>								<div class="printfooter">
				Retrieved from "<a href="http://en.wikipedia.org/w/index.php?title=Multiple_myeloma&amp;oldid=599977452">http://en.wikipedia.org/w/index.php?title=Multiple_myeloma&amp;oldid=599977452</a>"				</div>
												<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Hematologic_malignant_neoplasms" title="Category:Hematologic malignant neoplasms">Hematologic malignant neoplasms</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Articles_with_inconsistent_citation_formats" title="Category:Articles with inconsistent citation formats">Articles with inconsistent citation formats</a></li><li><a href="/wiki/Category:Wikipedia_articles_needing_clarification_from_December_2013" title="Category:Wikipedia articles needing clarification from December 2013">Wikipedia articles needing clarification from December 2013</a></li><li><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_March_2012" title="Category:Articles with unsourced statements from March 2012">Articles with unsourced statements from March 2012</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_February_2007" title="Category:Articles with unsourced statements from February 2007">Articles with unsourced statements from February 2007</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_July_2010" title="Category:Articles with unsourced statements from July 2010">Articles with unsourced statements from July 2010</a></li><li><a href="/wiki/Category:Articles_using_fixed_number_of_columns_in_reflist" title="Category:Articles using fixed number of columns in reflist">Articles using fixed number of columns in reflist</a></li><li><a href="/wiki/Category:Articles_with_Open_Directory_Project_links" title="Category:Articles with Open Directory Project links">Articles with Open Directory Project links</a></li></ul></div></div>												<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>
			<div id="mw-head">
				<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
	<h3 id="p-personal-label">Personal tools</h3>
	<ul>
<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Multiple+myeloma&amp;type=signup">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Multiple+myeloma" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>	</ul>
</div>
				<div id="left-navigation">
					<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
	<h3 id="p-namespaces-label">Namespaces</h3>
	<ul>
					<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Multiple_myeloma"  title="View the content page [c]" accesskey="c">Article</a></span></li>
					<li  id="ca-talk"><span><a href="/wiki/Talk:Multiple_myeloma"  title="Discussion about the content page [t]" accesskey="t">Talk</a></span></li>
			</ul>
</div>
<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
	<h3 id="mw-vector-current-variant">
		</h3>
	<h3 id="p-variants-label"><span>Variants</span><a href="#"></a></h3>
	<div class="menu">
		<ul>
					</ul>
	</div>
</div>
				</div>
				<div id="right-navigation">
					<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
	<h3 id="p-views-label">Views</h3>
	<ul>
					<li id="ca-view" class="selected"><span><a href="/wiki/Multiple_myeloma" >Read</a></span></li>
					<li id="ca-edit"><span><a href="/w/index.php?title=Multiple_myeloma&amp;action=edit"  title="You can edit this page. &#10;Please review your changes before saving. [e]" accesskey="e">Edit</a></span></li>
					<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Multiple_myeloma&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
			</ul>
</div>
<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
	<h3 id="p-cactions-label"><span>Actions</span><a href="#"></a></h3>
	<div class="menu">
		<ul>
					</ul>
	</div>
</div>
<div id="p-search" role="search">
	<h3><label for="searchInput">Search</label></h3>
	<form action="/w/index.php" id="searchform">
					<div id="simpleSearch">
					<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />		</div>
	</form>
</div>
				</div>
			</div>
			<div id="mw-panel">
					<div id="p-logo" role="banner"><a style="background-image: url(//upload.wikimedia.org/wikipedia/en/b/bc/Wiki.png);" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
				<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
	<h3 id='p-navigation-label'>Navigation</h3>
	<div class="body">
		<ul>
			<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li>
			<li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
			<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li>
			<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
			<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			<li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li>
			<li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikimedia Shop</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
	<h3 id='p-interaction-label'>Interaction</h3>
	<div class="body">
		<ul>
			<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			<li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
			<li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li>
			<li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
			<li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
	<h3 id='p-tb-label'>Tools</h3>
	<div class="body">
		<ul>
			<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Multiple_myeloma" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li>
			<li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Multiple_myeloma" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
			<li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li>
			<li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li>
			<li id="t-permalink"><a href="/w/index.php?title=Multiple_myeloma&amp;oldid=599977452" title="Permanent link to this revision of the page">Permanent link</a></li>
			<li id="t-info"><a href="/w/index.php?title=Multiple_myeloma&amp;action=info">Page information</a></li>
			<li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q467635" title="Link to connected data repository item [g]" accesskey="g">Data item</a></li>
<li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Multiple_myeloma&amp;id=599977452" title="Information on how to cite this page">Cite this page</a></li>		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
	<h3 id='p-coll-print_export-label'>Print/export</h3>
	<div class="body">
		<ul>
			<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Multiple+myeloma">Create a book</a></li>
			<li id="coll-download-as-rl"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Multiple+myeloma&amp;oldid=599977452&amp;writer=rl">Download as PDF</a></li>
			<li id="t-print"><a href="/w/index.php?title=Multiple_myeloma&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
	<h3 id='p-lang-label'>Languages</h3>
	<div class="body">
		<ul>
			<li class="interlanguage-link interwiki-ar"><a href="//ar.wikipedia.org/wiki/%D9%88%D8%B1%D9%85_%D9%86%D9%82%D9%88%D9%8A_%D9%85%D8%AA%D8%B9%D8%AF%D8%AF" title="ورم نقوي متعدد – Arabic" lang="ar" hreflang="ar">العربية</a></li>
			<li class="interlanguage-link interwiki-bn"><a href="//bn.wikipedia.org/wiki/%E0%A6%AE%E0%A6%9C%E0%A7%8D%E0%A6%9C%E0%A6%BE%E0%A6%95%E0%A7%8B%E0%A6%B7%E0%A6%BE%E0%A6%B0%E0%A7%8D%E0%A6%AC%E0%A7%81%E0%A6%A6" title="মজ্জাকোষার্বুদ – Bengali" lang="bn" hreflang="bn">বাংলা</a></li>
			<li class="interlanguage-link interwiki-ca"><a href="//ca.wikipedia.org/wiki/Mieloma_m%C3%BAltiple" title="Mieloma múltiple – Catalan" lang="ca" hreflang="ca">Català</a></li>
			<li class="interlanguage-link interwiki-cs"><a href="//cs.wikipedia.org/wiki/Mnoho%C4%8Detn%C3%BD_myelom" title="Mnohočetný myelom – Czech" lang="cs" hreflang="cs">Čeština</a></li>
			<li class="interlanguage-link interwiki-da"><a href="//da.wikipedia.org/wiki/Myelomatose" title="Myelomatose – Danish" lang="da" hreflang="da">Dansk</a></li>
			<li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Multiples_Myelom" title="Multiples Myelom – German" lang="de" hreflang="de">Deutsch</a></li>
			<li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/Mieloma_m%C3%BAltiple" title="Mieloma múltiple – Spanish" lang="es" hreflang="es">Español</a></li>
			<li class="interlanguage-link interwiki-fa"><a href="//fa.wikipedia.org/wiki/%D9%85%D9%88%D9%84%D8%AA%DB%8C%D9%BE%D9%84_%D9%85%DB%8C%D9%84%D9%88%D9%85%D8%A7" title="مولتیپل میلوما – Persian" lang="fa" hreflang="fa">فارسی</a></li>
			<li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/My%C3%A9lome_multiple" title="Myélome multiple – French" lang="fr" hreflang="fr">Français</a></li>
			<li class="interlanguage-link interwiki-ga"><a href="//ga.wikipedia.org/wiki/Mial%C3%B3ma_iolrach" title="Mialóma iolrach – Irish" lang="ga" hreflang="ga">Gaeilge</a></li>
			<li class="interlanguage-link interwiki-gl"><a href="//gl.wikipedia.org/wiki/Mieloma_m%C3%BAltiple" title="Mieloma múltiple – Galician" lang="gl" hreflang="gl">Galego</a></li>
			<li class="interlanguage-link interwiki-hi"><a href="//hi.wikipedia.org/wiki/%E0%A4%AE%E0%A4%B2%E0%A5%8D%E0%A4%9F%E0%A5%80%E0%A4%AA%E0%A4%B2_%E0%A4%AE%E0%A4%BE%E0%A4%87%E0%A4%B2%E0%A5%8B%E0%A4%AE%E0%A4%BE" title="मल्टीपल माइलोमा – Hindi" lang="hi" hreflang="hi">हिन्दी</a></li>
			<li class="interlanguage-link interwiki-id"><a href="//id.wikipedia.org/wiki/Sel_mieloma" title="Sel mieloma – Indonesian" lang="id" hreflang="id">Bahasa Indonesia</a></li>
			<li class="interlanguage-link interwiki-it"><a href="//it.wikipedia.org/wiki/Mieloma_multiplo" title="Mieloma multiplo – Italian" lang="it" hreflang="it">Italiano</a></li>
			<li class="interlanguage-link interwiki-he"><a href="//he.wikipedia.org/wiki/%D7%9E%D7%99%D7%90%D7%9C%D7%95%D7%9E%D7%94_%D7%A0%D7%A4%D7%95%D7%A6%D7%94" title="מיאלומה נפוצה – Hebrew" lang="he" hreflang="he">עברית</a></li>
			<li class="interlanguage-link interwiki-kk"><a href="//kk.wikipedia.org/wiki/%D0%9F%D0%BB%D0%B0%D0%B7%D0%BC%D0%BE%D1%86%D0%B8%D1%82%D0%BE%D0%BC%D0%B0" title="Плазмоцитома – Kazakh" lang="kk" hreflang="kk">Қазақша</a></li>
			<li class="interlanguage-link interwiki-lt"><a href="//lt.wikipedia.org/wiki/Mieloma" title="Mieloma – Lithuanian" lang="lt" hreflang="lt">Lietuvių</a></li>
			<li class="interlanguage-link interwiki-nl"><a href="//nl.wikipedia.org/wiki/Multipel_myeloom" title="Multipel myeloom – Dutch" lang="nl" hreflang="nl">Nederlands</a></li>
			<li class="interlanguage-link interwiki-ne"><a href="//ne.wikipedia.org/wiki/%E0%A4%AE%E0%A4%B2%E0%A5%8D%E0%A4%9F%E0%A4%BF%E0%A4%AA%E0%A4%B2_%E0%A4%AE%E0%A4%BE%E0%A4%87%E0%A4%B2%E0%A5%8B%E0%A4%AE%E0%A4%BE" title="मल्टिपल माइलोमा – Nepali" lang="ne" hreflang="ne">नेपाली</a></li>
			<li class="interlanguage-link interwiki-ja"><a href="//ja.wikipedia.org/wiki/%E5%A4%9A%E7%99%BA%E6%80%A7%E9%AA%A8%E9%AB%84%E8%85%AB" title="多発性骨髄腫 – Japanese" lang="ja" hreflang="ja">日本語</a></li>
			<li class="interlanguage-link interwiki-ps"><a href="//ps.wikipedia.org/wiki/%D9%85%D9%84%D9%BC%D9%8A%D9%BE%D9%84_%D9%85%D9%8A%D9%88%D9%84%D9%88%D9%85%D8%A7" title="ملټيپل ميولوما – Pashto" lang="ps" hreflang="ps">پښتو</a></li>
			<li class="interlanguage-link interwiki-pl"><a href="//pl.wikipedia.org/wiki/Szpiczak_mnogi" title="Szpiczak mnogi – Polish" lang="pl" hreflang="pl">Polski</a></li>
			<li class="interlanguage-link interwiki-pt"><a href="//pt.wikipedia.org/wiki/Mieloma_m%C3%BAltiplo" title="Mieloma múltiplo – Portuguese" lang="pt" hreflang="pt">Português</a></li>
			<li class="interlanguage-link interwiki-ru"><a href="//ru.wikipedia.org/wiki/%D0%9C%D0%B8%D0%B5%D0%BB%D0%BE%D0%BC%D0%BD%D0%B0%D1%8F_%D0%B1%D0%BE%D0%BB%D0%B5%D0%B7%D0%BD%D1%8C" title="Миеломная болезнь – Russian" lang="ru" hreflang="ru">Русский</a></li>
			<li class="interlanguage-link interwiki-simple"><a href="//simple.wikipedia.org/wiki/Multiple_myeloma" title="Multiple myeloma – Simple English" lang="simple" hreflang="simple">Simple English</a></li>
			<li class="interlanguage-link interwiki-fi"><a href="//fi.wikipedia.org/wiki/Myelooma" title="Myelooma – Finnish" lang="fi" hreflang="fi">Suomi</a></li>
			<li class="interlanguage-link interwiki-sv"><a href="//sv.wikipedia.org/wiki/Myelom" title="Myelom – Swedish" lang="sv" hreflang="sv">Svenska</a></li>
			<li class="interlanguage-link interwiki-tr"><a href="//tr.wikipedia.org/wiki/M%C3%BCltipl_miyelom" title="Mültipl miyelom – Turkish" lang="tr" hreflang="tr">Türkçe</a></li>
			<li class="interlanguage-link interwiki-uk"><a href="//uk.wikipedia.org/wiki/%D0%9C%D1%96%D1%94%D0%BB%D0%BE%D0%BC%D0%BD%D0%B0_%D1%85%D0%B2%D0%BE%D1%80%D0%BE%D0%B1%D0%B0" title="Мієломна хвороба – Ukrainian" lang="uk" hreflang="uk">Українська</a></li>
			<li class="interlanguage-link interwiki-zh"><a href="//zh.wikipedia.org/wiki/%E5%A4%9A%E7%99%BC%E6%80%A7%E9%AA%A8%E9%AB%93%E7%98%A4" title="多發性骨髓瘤 – Chinese" lang="zh" hreflang="zh">中文</a></li>
			<li class="uls-p-lang-dummy"><a href="#"></a></li>
			<li class="wbc-editpage"><a href="//www.wikidata.org/wiki/Q467635#sitelinks-wikipedia" title="Edit interlanguage links">Edit links</a></li>
		</ul>
	</div>
</div>
			</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 17 March 2014 at 07:48.<br /></li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy.</a> <br/>
Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a class="external" href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/wiki/Multiple_myeloma" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
					<li id="footer-copyrightico">
						<a href="//wikimediafoundation.org/"><img src="//bits.wikimedia.org/images/wikimedia-button.png" width="88" height="31" alt="Wikimedia Foundation"/></a>
					</li>
					<li id="footer-poweredbyico">
						<a href="//www.mediawiki.org/"><img src="//bits.wikimedia.org/static-1.23wmf19/skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" width="88" height="31" /></a>
					</li>
				</ul>
						<div style="clear:both"></div>
		</div>
		<script>/*<![CDATA[*/window.jQuery && jQuery.ready();/*]]>*/</script><script>if(window.mw){
mw.loader.state({"site":"loading","user":"ready","user.groups":"ready"});
}</script>
<script>if(window.mw){
mw.loader.load(["ext.cite","mobile.desktop","mediawiki.action.view.postEdit","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.DRN-wizard","ext.gadget.charinsert","mw.MwEmbedSupport.style","ext.navigationTiming","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage","skins.vector.collapsibleNav"],null,true);
}</script>
<script src="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=scripts&amp;skin=vector&amp;*"></script>
<!-- Served by mw1082 in 0.508 secs. -->
	</body>
</html>
